

Multi-Drug X(2-18) Drugs Rapid Test Key Cup with/without Adulteration (Urine)

Package Insert

Instruction Sheet for testing of any combination of the following drugs: ACE/AMP/BAR/BZO/BUP/COC/THC/MTD/MET/MDMA/MOP/MQL/OP//PCP/PPX/TCA/TML/KET/OXY/COT/EDDP/FYL/K2/6-MAM/MDA/ETG/CLO/LSD/MPD/ZOL/MEP/MDPV/DIA/ZOP/MCAT/T-ACL/CAF/CFYL/CAT/TRO/ALP/PGB/ZAL/MPRD/CNB/GAB/TZD/CAR/ABP/QTP/FLX/UR-144/KRA/TLD/α-PVP/MES/PAP/CIT/FKET/OZP/RPD/TAP/NND/SCOP/MTZ/HMO/ALC

Including Specimen Validity Tests (S.V.T.) for:

Oxidants/PCC, Specific Gravity, pH, Nitrite, Glutaraldehyde, Creatinine and Bleach

A rapid test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in human urine. For healthcare professionals including professionals at point of care sites. Immunoassay for in vitro diagnostic use only.

[INTENDED USE]

The Multi-Drug Rapid Test Cup is a rapid chromatographic immunoassay for the qualitative detection of multiple drugs and drug metabolites in urine at the following cut-off concentrations:

Calibrator	Cut-off (ng/mL)
Acetaminophen	5,000
d-Amphetamine	1,000/500/300
Secobarbital	300/200
Oxazepam	500/300/200/100
Buprenorphine	10/5
Benzoylecgonine	1,500/300/200/150/100
11-nor-Δ ⁹ -THC-9 COOH	300/200/150/50/30/25/ 20
Methadone	300/200
d-Methamphetamine	1,000/500/300/200
d,I-Methylenedioxymethamphetamine	1,000/500/300
Morphino	300/200/100
	300/200/100
	100
	2,000/1,000
	50/25
	300
	1,000/500/300
	500/300/200/100
	1,000/500/300/100
	300/100
	500/300/200/100/50/10
1 '	300/100
	00/40
·	20/10
	300/200/100
	50/30/25
	10
	500
	4 500/4 000/500/000
• •	1,500/1,000/500/300
Clonazepam	400/150
Lysergic Acid Diethylamide	50/20/10
Methylphenidate	300/150
Ritalin acid	1,000
Zolpidem	50
Mephedrone	500/100
3, 4-methylenedioxypyrovalerone	1,000/500/300
Diazepam	300/200
•	300/50
	500
7-Aminoclonazepam	300/200/100
	Acetaminophen d-Amphetamine Secobarbital Oxazepam Buprenorphine Benzoylecgonine 11-nor-Δ9-THC-9 COOH Methadone d-Methamphetamine d,I-Methylenedioxymethamphetamine Morphine Methaqualone Normeperidine Morphine Phencyclidine Propoxyphene Nortriptyline Cis-Tramadol Ketamine Oxycodone Cotinine 2-ethylidene-1,5-dimethyl- 3,3-diphenylpyrrolidine Norfentanyl Fentanyl JWH-018. JWH-073 6-MAM (±) 3,4-Methylenedioxy- Amphetamine Ethyl- β-D-Glucuronide Clonazepam Lysergic Acid Diethylamide Methylphenidate Ritalin acid Zolpidem Mephedrone 3, 4-methylenedioxypyrovalerone Diazepam Zopiclone S(-)-Methcathinone

Carfentanyl (CFYL)	Carfentanyl	500/250
Cannabinol (CNB)	Cannabinol	500
Caffeine (CAF)	Caffeine	1,000
Cathine (CAT)	(+)-Norpseudoephedrine	150
Tropicamide (TRO)	Tropicamide	350
Alprazolam (ALP)	Alprazolam	100
Pregabaline (PGB)	Pregabaline	50,000/500
Gabapentin (GAB)	Gabapentin	2,000
Zaleplon (ZAL)	Zaleplon	100
Carisoprodol (CAR)	Carisoprodol	2,000/1,000/500
AB-PINACA (ABP)	AB-PINACA	10
Quetiazepam (QTP)	Quetiazepam	1,000
Fluoxetine (FLX)	Fluoxetine	500
UR-144	UR-144 5-Pentanoic acid	25
Kratom (KRA)	Mitragynine	300
Tilidine (TLD)	Nortilidine	50
Trazodone (TZD)	Trazodone	200
Alpha-Pyrrolidinovalerophenone (α-PVP)	Alpha-Pyrrolidinovalerophenone	2,000/1,000/500/300
Mescaline (MES)	Mescaline	300/100
Papaverine (PAP)	Papaverine	500
Citalopram (CIT)	Citalopram	500
Fluoketamine (FKET)	Fluoketamine	1,000
Olanzapine (OZP)	Olanzapine	1,000
Risperidone (RPD)	Risperidone	150
Tapentadol (TAP)	Tapentadol	1,000
N,N-Dimethyltryptamine (NND)	N,N-Dimethyltryptamine	1,000
Scopolamine (SCOP)	Scopolamine	500
Mirtazapine (MTZ)	Desmethylmirtazapine	500
Hydromorphone (HMO)	Hydromorphone	500/300/250

Test	Calibrator	Cut-off
Alcohol(ALC)	Alcohol	0.02%

Configurations of the Multi-Drug Rapid Test Cup come with any combination of the above listed drug analytes with or without S.V.T. This assay provides only a preliminary test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

[SUMMARY OF ADULTERATION]

Adulteration is the tampering of a urine specimen with the intention of altering the test results. The use of adulterants can cause false negative results in drug tests by either interfering with the screening test and/or destroying the drugs present in the urine. Dilution may also be employed in an attempt to produce false negative drug test results.

One of the best ways to test for adulteration or dilution is to determine certain urinary characteristics such as pH, specific gravity and creatinine and to detect the presence of oxidants/PCC, nitrites or glutaraldehyde in urine.

[PRINCIPLE (FOR DOA TESTS EXCLUDING ALCOHOL)]

During testing, a urine specimen migrates upward by capillary action. A drug, if present in the urine specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test region of the specific drug dipstick. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test region.

A drug-positive urine specimen will not generate a colored line in the specific test region of the dipstick because of drug competition, while a drug-negative urine specimen will generate a line in the test region because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

[PRINCIPLE OF ADULTERATION]

Oxidants/PCC (Pyridiniumchlorochromate) tests for the presence of oxidizing agents such as bleach and hydrogen peroxide. Pyridiniumchlorochromate (sold under the brand name Urine Luck) is a commonly used adulterant. Normal human urine should not contain oxidants of PCC.

Specific gravity tests for sample dilution. The normal range is from 1.003 to 1.030. Values outside this range may be the result of specimen dilution or adulteration.

pH tests for the presence of acidic or alkaline adulterants in urine. Normal pH levels should be in the range of 4.0 to 9.0. Values outside of this range may indicate the sample has been altered.

Nitrite tests for commonly used commercial adulterants such as Klear and Whizzies. They work by oxidizing the major cannabinoid metabolite THC-COOH.³ Normal urine should contain no trace of nitrite. Positive results generally indicate the presence of an adulterant.

Glutaraldehyde tests for the presence of an aldehyde. Adulterants such as Urin Aid and Clear Choice contain glutaraldehyde which may cause false negative results by disrupting the enzyme used in some immunoassay tests.³ Glutaraldehyde is not normally found in urine; therefore, detection of glutaraldehyde in a urine specimen is generally an indicator of adulteration.

Creatinine is a waste product of creatine; an amino-acid contained in muscle tissue and found in urine. A person may attempt to foil a test by drinking excessive amounts of water or diuretics such as herbal teas to flush the system. Creatinine and specific gravity are two ways to check for dilution and flushing, which are the most common mechanisms used in an attempt to circumvent drug testing. Low Creatinine and specific gravity levels may indicate dilute urine. The absence of Creatinine (<5 mg/dL) is indicative of a specimen not consistent with human uring

Bleach tests for the presence of bleach. Bleach refers to a number of chemicals which remove color, whiten or disinfect, often by oxidation, Bleaches are used as household chemicals to whiten clothes and remove stains and as disinfectants. Normal human urine should not contain bleach

[PRINCIPLE (FOR ALCOHOL)]

The urine Alcohol Rapid Test Cup consists of a plastic strip with a reaction pad attached at the tip. On contact with alcohol, the reaction pad will change colors depending on the concentration of alcohol present. This is based on the high specificity of alcohol oxidase for ethyl alcohol in the presence of peroxidase and enzyme substrate such as TMB.

[REAGENTS(FOR DOA TESTS EXCLUDING ALCOHOL)]

Each test line contains anti-drug mouse monoclonal antibody and corresponding drug-protein conjugates. The control line contains goat anti-rabbit IgG polyclonal antibodies and rabbit IgG.

[REAGENTS (FOR ALCOHOL)]

Tetramethylbenzidine, Alcohol Oxidase, Peroxidase

[S.V.T REAGENTS]

Adulteration Pad	Reactive indicator	Buffers and non-reactive ingredients
Creatinine	0.04%	99.96%
Nitrite	0.07%	99.93%
Bleach	0.39%	99.61%
Glutaraldehyde	0.02%	99.98%
рН	0.06%	99.94%
Specific Gravity	0.25%	99.75%
Oxidants / PCC	0.36%	99.64%

[PRECAUTIONS]

- For healthcare professionals including professionals at point of care sites.
- Immunoassay for in vitro diagnostic use only. The test should remain in the sealed pouch until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
- The used test should be discarded according to local regulations.

STORAGE AND STABILITY

Store as packaged in the sealed pouch at 2-30°C. The test is stable through the expiration date printed on the sealed pouch. The Test must remain in the sealed pouch until use. **DO NOT FREEZE.** Do not use beyond the expiration date.

[SPECIMEN COLLECTION AND PREPARATION]

Urine Assav

The urine specimen should be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear specimen for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed well before testing. When testing cards with S.V.T. or Alcohol storage of urine specimens should not exceed 2 hours at room temperature or 4 hours refrigerated prior to testing.

[MATERIALS]

Materials Provided

- · Test Cups
- Package Insert
- Adulteration Color Chart (when applicable)

Materials Required But Not Provided

Timer

pouch and use it within one hour

· Specimen collection containers


[DIRECTIONS FOR USE]

Allow the test, urine specimen, and/or controls to reach room temperature (15-30°C) prior

- to testing. 1. Bring the pouch to room temperature before opening it. Remove the cup from the sealed
- 2. Pull tab to remove cap, collect specimen in the cup and secure cap by pressing down on all
- 3. Check the temperature label (Temp Label) up to 4 minutes after specimen collection. A green color will appear to indicate the temperature of the urine specimen. The proper range for an unadulterated specimen is 32-38°C (90-100°F).
- 4. Check the cap for a tight seal, date and initial the security seal label, then place it over the cap.
- 5. Remove one key from the kit, place the cup on a flat surface, and push the key into the socket of the cup to begin the test. Start timer.
- 6. Remove the peel off label covering the test results and wait for the colored line(s) to appear. Read the adulteration strips and alcohol strip between 3-5 minutes with the help of color chart provided separately/on foil pouch. Read drug strip results at 5 minutes. Do not interpret results after 10 minutes.

Place cup on a flat surface, insert key and push in.

Peel off label to view results.






Wait 5 minutes to read drug results.



Interpret adulteration strips and Alcohol strip between 3-5 minutes. See enclosed color chart for interpretation.



[INTERPRETATION OF RESULTS]

(Please refer to the illustration above)

NEGATIVE:* A colored line appears in the control region (C) and another colored line appears in the test region (T). This negative result means that the concentrations in the urine sample are below the designated cut-off levels for a particular drug tested.

*NOTE: The shade of the colored lines(s) in the test region (T) may vary. The result should be considered negative whenever there is even a faint line.

POSITIVE: A colored line appears in the control region (C) and no line appears in the test region (T). The positive result means that the drug concentration in the urine sample is greater than the designated cut-off for a specific drug.

INVALID: No line appears in the control region (C). Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Read the directions again and repeat the test with a new test. If the result is still invalid, contact your manufacturer.

[INTERPRETATION OF RESULTS (S.V.T/ ADULTERATION)]

(Please refer to the color chart)

Semi-Quantitative results are obtained by visually comparing the reacted color blocks on the strip to the printed color blocks on the color chart. No instrumentation is required.

[INTERPRETATION OF RESULTS (ALCOHOL STRIP)]

Negative: Almost no color change by comparing with the background. The negative result indicates that the urine alcohol level is less than 0.02%.

Positive: A distinct color developed all over the pad. The positive result indicates that the urine alcohol concentration is 0.02% or higher.

Invalid: The test should be considered invalid if only the edge of the reactive pad turned color that might be ascribed to insufficient sampling. The subject should be re-tested. Besides, if the color pad has a blue color before applying urine sample, do not use the test.

[QUALITY CONTROL]

A procedural control is included in the test. A line appearing in the control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit. However, it is recommended that positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify proper test performance.

[LIMITATIONS]

- 1. The Multi-Drug Rapid Test Cup provides only a qualitative, preliminary result. A secondary analytical method must be used to obtain a confirmed result. Gas Chromatography /Mass Spectrometry (GC/MS) is the preferred confirmatory method. 4,5
- 2. There is a possibility that technical or procedural errors, as well as interfering substances in the urine specimen may cause erroneous results.
- 3. Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
- 4. A positive result does not indicate level or intoxication, administration route or concentration
- 5. A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.
- 6. This test does not distinguish between drugs of abuse and certain medications.
- 7. A positive test result may be obtained from certain foods or food supplements.

[S.V.T/ ADULTERATION LIMITATIONS]

- 1. The adulteration tests included with the product are meant to aid in the determination of abnormal specimens. While comprehensive, these tests are not meant to be an "all-inclusive" representation of possible adulterants.
- 2. Oxidants/PCC: Normal human urine should not contain oxidants or PCC. The presence of high levels of antioxidants in the specimen, such as ascorbic acid, may result in false negative results for the oxidants/PCC pad.
- 3. Specific Gravity: Elevated levels of protein in urine may cause abnormally high specific gravity values.
- 4. Nitrite: Nitrite is not a normal component of human urine. However, nitrite found in urine may indicate urinary tract infections or bacterial infections. Nitrite levels of >20 mg/dL may produce false positive glutaraldehyde results.
- 5. Glutaraldehyde: is not normally found in urine. However certain metabolic abnormalities such as ketoacidosis (fasting, uncontrolled diabetes or high protein diets) may interfere with
- 6. Creatinine: Normal Creatinine levels are between 20 and 350 mg/dL. Under rare conditions. certain kidney diseases may show dilute urine.
- 7. Bleach: Normal human urine should not contain bleach. The presence of high levels of bleach in the specimen may result in false negative results for the bleach pad.
- 8. pH: Normal pH levels are between 4.0 and 9.0.

[PERFORMANCE CHARACTERISTICS]

Accuracy % Agreement with GC/MS

				n Agici							
	ACE	AMP	AMP	AMP	BAR	BAR	BZO	BZO	BZO	BZO	BUP
	5,000	1,000	500	300	300	200	500	300	200	100	10
Positive Agreement	93.5%	98.1%	99.1%	99.1%	96.1%	95.3%	98.2%	98.4%	99.2%	99.2%	99.1%
Negative Agreement	98.6%	97.9%	98.6%	98.5%	98.6%	97.9%	97.8%	99.2%	98.4%	97.5%	>99.9 %
Total Results	97.0%	98.0%	98.8%	98.8%	97.6%	96.8%	98.0%	98.8%	98.8%	98.4%	99.6%
	BUP	COC	COC	COC	COC	THC	THC	THC	THC	THC	MTD
	5	300	200	150	100	300	150	50	25	20	300
Positive Agreement	99.1%	98.2%	>99.9 %	98.3%	99.2%	95.5%	94.5%	97.9%	96.9%	94.8%	98.9%

Negative Agreement	>99.9	97.8%	>99.9	97.0%	97.0%	98.1%	97.5%	98.1%	97.4%	99.3%	98.8%
Total Results	99.6%	98.0%	100.0 %	97.6%	98.0%	97.2%	96.4%	98.0%	97.2%	97.6%	98.8%
	MTD 200	MET 1,000	MET 500	MET 300	MDMA 1,000	MDMA 500	MDMA 300	MOP/ OPI 300	MOP/ OPI 100	MQL 300	OPI 2,000
Positive Agreement	98.9%	96.2%	97.6%	97.8%	98.0%	98.1%	98.1%	95.0%	97.0%	89.8%	96.7%
Negative Agreement	98.7%	97.1%	97.0%	97.5%	99.3%	99.3%	99.3%	95.3%	96.6%	93.2%	93.8%
Total Results	98.8%	96.8%	97.2%	97.6%	98.8%	98.8%	98.8%	95.2%	96.8%	92.0%	95.2%
	PCP 25	PPX 300	TCA 1,000	TCA 500	TML 100	TML 200	TML 300	KET 1,000	KET 500	KET 300	KET 100
Positive Agreement	92.4%	96.0%	94.8%	94.9%	88.2%	88.2%	88.0%	97.5%	97.6%	96.7%	96.0%
Negative Agreement	96.8%	94.0%	91.6%	92.1%	92.4%	96.2%	96.2%	98.2%	98.2%	97.5%	97.3%
Total Results	95.2%	94.8%	92.8%	93.2%	90.8%	93.2%	93.2%	98.0%	98.0%	97.2%	96.8%
		·							I		
	0XY 100	OXY 300	COT 500	COT 200	100	COT 50	COT 10	EDDP 300	EDDP 100	FYL 20	FYL 10
Positive	97.7%	96.5%	95.7%		97.9%		97.8%	97.9%	96.9%	98.8%	98.8%
Agreement Negative Agreement	99.4%	99.4%	96.1%	97.5%	98.1%	97.5%	98.1%	99.4%	96.7%	99.4%	99.4%
Total Results	98.8%	98.4%	96.0%	97.2%	98.0%	97.2%	98.0%	98.8%	96.8%	99.2%	99.2%
	K2 50	K2 30	6-MAM 10	MDA 500	ETG 500	ETG 1,000	CLO 400	CLO 150	LSD 10	LSD 20	LSD 50
Positive Agreement											
	50	30	10	500 98.1%	500 97.6%	1,000	400	150	10	20	50
Agreement Negative	50 97.5%	30 97.6%	10 97.7%	500 98.1% 97.9%	500 97.6%	1,000 95.3%	400 97.1%	150 99.0%	10 94.3%	20 94.3% 98.5%	50 94.1% 98.5%
Agreement Negative Agreement Total	50 97.5% 98.2% 98.0%	30 97.6% 98.8% 98.4%	97.7% 98.1% 98.0%	500 98.1% 97.9% 98.0%	500 97.6% 99.4% 98.8%	1,000 95.3% 99.4% 98.0%	400 97.1% 99.3% 98.4%	99.0% 98.6% 98.8%	10 94.3% 98.5% 97.0%	20 94.3% 98.5% 97.0%	50 94.1% 98.5% 97.0%
Agreement Negative Agreement Total	50 97.5% 98.2% 98.0%	30 97.6% 98.8% 98.4%	10 97.7% 98.1% 98.0%	500 98.1% 97.9% 98.0%	500 97.6% 99.4% 98.8%	1,000 95.3% 99.4% 98.0%	400 97.1% 99.3% 98.4% MCAT	150 99.0% 98.6% 98.8%	10 94.3% 98.5% 97.0%	20 94.3% 98.5% 97.0%	50 94.1% 98.5% 97.0%
Agreement Negative Agreement Total Results Positive	50 97.5% 98.2% 98.0%	30 97.6% 98.8% 98.4%	97.7% 98.1% 98.0%	500 98.1% 97.9% 98.0%	500 97.6% 99.4% 98.8%	1,000 95.3% 99.4% 98.0%	400 97.1% 99.3% 98.4%	99.0% 98.6% 98.8%	10 94.3% 98.5% 97.0%	20 94.3% 98.5% 97.0%	50 94.1% 98.5% 97.0%
Agreement Negative Agreement Total Results Positive Agreement Negative	97.5% 98.2% 98.0% MPD 300	30 97.6% 98.8% 98.4% MPD 1,000	10 97.7% 98.1% 98.0% ZOL 50	98.1% 97.9% 98.0% DIA 300	97.6% 99.4% 98.8% DIA 200	1,000 95.3% 99.4% 98.0% ZOP 50	99.3% 98.4% MCAT 500	150 99.0% 98.6% 98.8% 7-ACL 300	10 94.3% 98.5% 97.0% 7-ACL 200	20 94.3% 98.5% 97.0% 7-ACL 100	50 94.1% 98.5% 97.0% CFYL 500
Agreement Negative Agreement Total Results Positive Agreement Negative Agreement Total	97.5% 98.2% 98.0% MPD 300 94.6%	30 97.6% 98.8% 98.4% MPD 1,000 94.6%	10 97.7% 98.1% 98.0% ZOL 50 90.9%	500 98.1% 97.9% 98.0% DIA 300 98.4%	500 97.6% 99.4% 98.8% DIA 200 98.4%	1,000 95.3% 99.4% 98.0% ZOP 50 86.4% 97.2%	97.1% 99.3% 98.4% MCAT 500 90.9%	150 99.0% 98.6% 98.8% 7-ACL 300 94.1%	10 94.3% 98.5% 97.0% 7-ACL 200 94.6%	20 94.3% 98.5% 97.0% 7-ACL 100 94.7% 97.5%	94.1% 98.5% 97.0% CFYL 500 94.7%
Agreement Negative Agreement Total Results Positive Agreement Negative Agreement	97.5% 98.2% 98.0% MPD 300 94.6% 98.4%	30 97.6% 98.8% 98.4% MPD 1,000 94.6% 98.4%	10 97.7% 98.1% 98.0% ZOL 50 90.9% 97.1%	500 98.1% 97.9% 98.0% DIA 300 98.4% 99.2%	500 97.6% 99.4% 98.8% DIA 200 98.4% 99.2%	1,000 95.3% 99.4% 98.0% ZOP 50 86.4% 97.2%	400 97.1% 99.3% 98.4% MCAT 500 90.9% 95.0%	150 99.0% 98.6% 98.8% 7-ACL 300 94.1% 97.7%	10 94.3% 98.5% 97.0% 7-ACL 200 94.6% 97.6%	20 94.3% 98.5% 97.0% 7-ACL 100 94.7% 97.5%	50 94.1% 98.5% 97.0% CFYL 500 94.7% 98.6%
Agreement Negative Agreement Total Results Positive Agreement Negative Agreement Total	97.5% 98.2% 98.0% MPD 300 94.6% 97.0%	30 97.6% 98.8% 98.4% MPD 1,000 94.6% 97.0%	10 97.7% 98.1% 98.0% ZOL 50 90.9% 97.1%	500 98.1% 97.9% 98.0% DIA 300 98.4% 99.2%	500 97.6% 99.4% 98.8% DIA 200 98.4% 99.2%	1,000 95.3% 99.4% 98.0% ZOP 50 86.4% 97.2%	400 97.1% 99.3% 98.4% MCAT 500 90.9% 95.0% 94.1%	150 99.0% 98.6% 98.8% 7-ACL 300 94.1% 97.7% 96.2%	10 94.3% 98.5% 97.0% 7-ACL 200 94.6% 97.6% 96.2%	20 94.3% 98.5% 97.0% 7-ACL 100 94.7% 97.5%	94.1% 98.5% 97.0% CFYL 500 94.7% 98.6% 97.3%
Agreement Negative Agreement Total Results Positive Agreement Total Agreement Total Results Positive	50 97.5% 98.2% 98.0% MPD 300 94.6% 98.4%	30 97.6% 98.8% 98.4% MPD 1,000 94.6% 98.4%	10 97.7% 98.1% 98.0% ZOL 50 90.9% 97.1%	500 98.1% 97.9% 98.0% DIA 300 98.4% 99.2%	500 97.6% 99.4% 98.8% DIA 200 98.4% 99.2%	1,000 95.3% 99.4% 98.0% ZOP 50 86.4% 97.2%	400 97.1% 99.3% 98.4% MCAT 500 90.9% 95.0%	150 99.0% 98.6% 98.8% 7-ACL 300 94.1% 97.7%	10 94.3% 98.5% 97.0% 7-ACL 200 94.6% 97.6%	20 94.3% 98.5% 97.0% 7-ACL 100 94.7% 97.5%	50 94.1% 98.5% 97.0% CFYL 500 94.7% 98.6%
Agreement Negative Agreement Total Results Positive Agreement Total Regative Agreement Total Results Positive Agreement Negative Agreement Negative Agreement Negative	97.5% 98.2% 98.0% MPD 300 94.6% 97.0% CAF 1,000	30 97.6% 98.8% 98.4% MPD 1,000 94.6% 97.0% CAT 150	10 97.7% 98.1% 98.0% ZOL 50 90.9% 97.1% 95.6% TRO 350	500 98.1% 97.9% 98.0% DIA 300 98.4% 99.2% 98.8%	500 97.6% 99.4% 98.8% DIA 200 98.4% 99.2% 98.8%	1,000 95.3% 99.4% 98.0% ZOP 50 86.4% 97.2% 94.6%	400 97.1% 99.3% 98.4% MCAT 500 90.9% 95.0% 94.1%	150 99.0% 98.6% 98.8% 7-ACL 300 94.1% 97.7% 96.2%	10 94.3% 98.5% 97.0% 7-ACL 200 94.6% 97.6% 96.2% α-PVP 1,000	20 94.3% 98.5% 97.0% 7-ACL 100 94.7% 96.2% CNB 500	50 94.1% 98.5% 97.0% CFYL 500 94.7% 98.6% 97.3%
Agreement Negative Agreement Total Results Positive Agreement Total Results Positive Agreement Total Positive Agreement Total	98.2% 98.0% MPD 300 94.6% 98.4% 97.0% CAF 1,000 91.3%	30 97.6% 98.8% 98.4% MPD 1,000 94.6% 97.0% CAT 150 90.5%	10 97.7% 98.1% 98.0% 2OL 50 90.9% 97.1% 95.6% TRO 350 92.0%	500 98.1% 97.9% 98.0% DIA 300 98.4% 99.2% 98.8% MDPV 1,000 93.3%	500 97.6% 99.4% 98.8% DIA 200 98.4% 99.2% 98.8% MDPV 500 93.1%	1,000 95.3% 99.4% 98.0% ZOP 50 86.4% 97.2% 94.6%	400 97.1% 99.3% 98.4% MCAT 500 90.9% 94.1% ALP 100 90.9%	150 99.0% 98.6% 98.8% 7-ACL 300 94.1% 96.2% ABP 10	10 94.3% 98.5% 97.0% 7-ACL 200 94.6% 97.6% 96.2% α-PVP 1,000 92.1%	20 94.3% 98.5% 97.0% 7-ACL 100 94.7% 96.2% CNB 500 95.8%	50 94.1% 98.5% 97.0% CFYL 500 94.7% 98.6% 97.3% MPRD 100 95.0%
Agreement Negative Agreement Total Results Positive Agreement Total Regative Agreement Total Results	97.5% 98.2% 98.0% MPD 300 94.6% 97.0% CAF 1,000 91.3% 95.7%	30 97.6% 98.8% 98.4% MPD 1,000 94.6% 97.0% CAT 150 90.5% 97.3%	10 97.7% 98.1% 98.0% ZOL 50 90.9% 97.1% 95.6% TRO 350 92.0%	500 98.1% 97.9% 98.0% DIA 300 98.4% 99.2% 98.8% MDPV 1,000 93.3% 98.6%	500 97.6% 99.4% 98.8% DIA 200 98.4% 99.2% 98.8% MDPV 500 93.1% 98.3%	1,000 95.3% 99.4% 98.0% ZOP 50 86.4% 97.2% 94.6% MEP 100 90.5% 97.0%	400 97.1% 99.3% 98.4% MCAT 500 90.9% 94.1% ALP 100 90.9% 97.4%	150 99.0% 98.6% 98.8% 7-ACL 300 94.1% 96.2% ABP 10 92.0% 97.1%	10 94.3% 98.5% 97.0% 7-ACL 200 94.6% 96.2% a-PVP 1,000 92.1% 96.8%	20 94.3% 98.5% 97.0% 7-ACL 100 94.7% 96.2% CNB 500 95.8% 97.6%	94.1% 98.5% 97.0% CFYL 500 94.7% 98.6% 97.3% MPRD 100 94.2%
Agreement Negative Agreement Total Results Positive Agreement Total Results Positive Agreement Total Positive Agreement Total	97.5% 98.2% 98.0% 98.0% MPD 300 94.6% 97.0% CAF 1,000 91.3% 95.7%	30 97.6% 98.8% 98.4% 94.6% 97.0% CAT 150 90.5% 97.3%	10 97.7% 98.1% 98.0% ZOL 50 90.9% 97.1% 95.6% TRO 350 92.0%	500 98.1% 97.9% 98.0% DIA 300 98.4% 99.2% 98.8% MDPV 1,000 93.3% 98.6%	500 97.6% 99.4% 98.8% DIA 200 98.4% 99.2% 98.8% MDPV 500 93.1% 98.3% 96.6%	1,000 95.3% 99.4% 98.0% ZOP 50 86.4% 97.2% 94.6% MEP 100 90.5% 97.0%	400 97.1% 99.3% 98.4% MCAT 500 90.9% 94.1% ALP 100 90.9% 97.4%	99.0% 98.6% 98.8% 7-ACL 300 94.1% 97.7% 96.2% ABP 10 92.0% 97.1%	10 94.3% 98.5% 97.0% 7-ACL 200 94.6% 97.6% 96.2% α-PVP 1.000 92.1% 96.8% 95.0%	20 94.3% 98.5% 97.0% 7-ACL 100 94.7% 97.5% 96.2% CNB 500 95.8% 97.6%	94.1% 98.5% 97.0% CFYL 500 94.7% 98.6% 97.3% MPRD 100 95.0% 94.4%
Agreement Negative Agreement Total Results Positive Agreement Total Results Positive Agreement Total Positive Agreement Total	97.5% 98.2% 98.0% MPD 300 94.6% 97.0% CAF 1,000 91.3% 95.7%	30 97.6% 98.8% 98.4% MPD 1,000 94.6% 97.0% CAT 150 90.5% 97.3%	10 97.7% 98.1% 98.0% ZOL 50 90.9% 97.1% 95.6% TRO 350 92.0% 97.0%	500 98.1% 97.9% 98.0% DIA 300 98.4% 99.2% 98.8% MDPV 1,000 93.3% 98.6%	500 97.6% 99.4% 98.8% DIA 200 98.4% 99.2% 98.8% MDPV 500 93.1% 98.3%	1,000 95.3% 99.4% 98.0% ZOP 50 86.4% 97.2% 94.6% MEP 100 90.5% 97.0%	400 97.1% 99.3% 98.4% MCAT 500 90.9% 95.0% 94.1% ALP 100 90.9% 97.4%	150 99.0% 98.6% 98.8% 7-ACL 300 94.1% 96.2% ABP 10 92.0% 97.1%	10 94.3% 98.5% 97.0% 7-ACL 200 94.6% 96.2% a-PVP 1,000 92.1% 96.8%	20 94.3% 98.5% 97.0% 7-ACL 100 94.7% 96.2% CNB 500 95.8% 97.6%	94.1% 98.5% 97.0% CFYL 500 94.7% 98.6% 97.3% MPRD 100 94.2%
Agreement Negative Agreement Total Results Positive Agreement Total Results Positive Agreement Total Positive Agreement Total	97.5% 98.2% 98.0% 98.0% 94.6% 97.0% CAF 1,000 91.3% 95.7% 94.6%	30 97.6% 98.8% 98.4% 98.46% 97.0% CAT 150 90.5% 97.3% 95.8%	97.7% 98.1% 98.0% ZOL 50 90.9% 97.1% 95.6% TRO 350 92.0% 97.0% UR- 144	98.1% 97.9% 98.0% 98.0% 98.0% 99.2% 99.2% 99.3% 99.3% 97.0%	97.6% 99.4% 98.8% DIA 200 98.4% 99.2% 98.8% MDPV 500 93.1% 96.6%	1,000 95.3% 99.4% 98.0% 2OP 50 86.4% 97.2% 94.6% MEP 100 90.5% 97.0% 95.4%	400 97.1% 99.3% 98.4% MCAT 500 95.0% 95.0% 94.1% ALP 100 90.9% 97.4% 95.9%	150 99.0% 98.6% 98.8% 7-ACL 300 94.1% 97.7% 96.2% ABP 10 92.0% 97.1% 95.8%	10 94.3% 98.5% 97.0% 7-ACL 200 94.6% 97.6% 96.2% α-PVP 1,000 92.1% 96.8% 95.0%	20 94.3% 98.5% 97.0% 7-ACL 100 94.7% 97.5% 96.2% CNB 500 95.8% 97.6% 96.9%	94.1% 98.5% 97.0% CFYL 500 94.7% 98.6% 97.3% MPRD 100 95.0% 94.4%

Negative	97.3	20/.	96.1%	98.4%	97.4%	97.6%	98.5%	96.0	% 99.4	% 95.2	2% 98.3%	6 98.39
Agreement	31.3	, /0	JU. 170	30.470	31.470	31.070	30.0%	0.00	70 33.4	70 90.2	- /0 30.37	0 30.3
Total	95.9	10/.	95.2%	98.0%	96.7%	96.9%	96.7%	95.6	% 99.2	% 94.0	97.9%	6 97.99
Results	33.8	/0	93.276	90.076	30.7 /6	30.376	90.7 70	95.0	/6 99.2	76 34.0	076 31.37	0 91.9
	PA	ıΡ	KRA	CAR	FLX	K2	CIT	FKE	T RPI	FY	L FYL	CFYI
	50		300	2,000	500	25	500	1,00				250
Positive												
Agreement	96.	9%	95.7%	95.0%	97.1%	97.6%	93.3%	96.7	% 93.3	% 98.8	97.5%	94.79
Negative	98.	no/.	08 30/	94.2%	96.6%	98.2%	95.5%	97.0	% 95.59	% 99.4	9/ 00 49/	98.69
Agreement	90.	0 76	30.376	34.2 /0	30.076	90.2 /6	90.070	97.0	/6 95.5	/6 33.4	70 33.470	30.07
Total	07	20/	07.69/	04 49/	96.8%	00 00/	04 00/	96.9	0/ 04 00	00.0	% 98.8%	07.20
Results	31.	0 76	91.076	34.470	90.076	90.076	34.070	90.9	/6 34.0	76 33.2	. 76 30.0 76	91.3
	F	GB	MES	OZF	MDF	V α-P	VP a	-PVP	TAP	NNE	SCOF	MTZ
		500	300					300	1,000	1,00		500
Positive												
Agreemen	t 95	5.2%	95.89	% 95.8°	% 93.8	% 86.8	3% 92	2.1%	94.4%	96.7	% 93.5%	93.39
Negative			1							T		İ
Agreemen	t 96	3.3%	97.6	97.69	% 97.1	% 96.8	3% 98	5.2%	98.2%	97.0	% 98.6%	95.69
Total			0		, , , ,	,		1.051	00 == 1			
Results	96	3.0%	96.9	% 96.9°	% 96.1	% 93.0)% 94	4.0%	96.7%	96.9	% 97.0%	94.99
	CC	DΤ	THC	THC	MEP	MPD	OPI	I P	CP TN	ΛL T	CA CAR	FYL
	30	00	200	30	500	150	1,00		50 50		00 1,00	300
Positive												
Agreement	97.	7%	93.4%	97.9%	95.2%	91.9%	95.99	% 92	.3% 92.	9% 94.	90.09	6 97.0°
Negative		=0/	07.50/	00.40/	00 50/	00.40/	00.00		201 20	40/ 00	40/ 00 40	
Agreement	97.	5%	97.5%	98.1%	98.5%	98.4%	93.89	% 96	.9% 98.	1% 92.	1% 98.19	6 98.9°
Total	07	CO/	96.0%	98.0%	97.7%	96.0%	94.89	0.5	.2% 96.	00/ 02	2% 95.89	/ 00 00
Results	97.	070	90.0%	96.0%	97.770	90.0%	94.0	76 95	.2% 90.	976 93.	2% 93.67	6 96.0
			IMO	НМО	НМ	<u> </u>	ИЕТ	CA	D (COC	ETG	ZOP
			250	300	500		200	50		,500	1,500	300
Positive	,											
Agreeme	nt	93	3.8%	91.7%	91.7	% 9	7.6%	90.	0% 9	2.0%	97.7%	90.9%
Negativ		-						-00	20/	0.00/		07.00/
Agreeme				00 -01								
		91	7.5%	98.7%	98.7	% 9	7.0%	92.	3% 9	8.3%	99.4%	97.2%
Total Res	ulto											
	ults		7.5% 6.1%	96.1%	96.1	% 9	7.2%	91.	7% 9	5.2%	99.4%	
		96	6.1%	96.1% % Ag	96.1	% 9	7.2% Comm	91.	7% 9 Kit	5.2%	98.8%	95.7%
	F	96	6.1% AMI	96.1% % Ag BA	96.1 reemer	% 9' ot with 0 O BL	7.2% Commo	91. ercial	7% 9 Kit COC	5.2% THC	98.8%	95.7% MPD
	F	96	6.1% AMI 1,00	96.1% % Ag BA 0/ 300	96.1 96.1 reemer R BZ D/ 50	% 9' ht with (O BL 0/ 10	7.2% Commo	91. ercial COC 300/	7% 9 Kit COC 1,500/	5.2% THC 150/50	98.8% THC 0/ 300/	95.7% MPD 1,000
	F	96	6.1% AMI 1,00 500	96.1% % Ag P BA 0/ 300 // 20	96.1 reemer R BZ D/ 50 0 30	% 9' of with 0 O BL 0/ 10 0/	7.2% Commo	91. ercial	7% 9 Kit COC 1,500/ 200/	5.2% THC	98.8% THC 0/ 300/ 200/30/	95.7% MPD 1,000 300/
	F	96	6.1% AMI 1,00	96.1% % Ag P BA 0/ 300 // 20	96.1 reemer R BZ D/ 50 0 30 20	% 9' ot with (O BL O/ 10 O/ O/ O/	7.2% Commo	91. ercial COC 300/	7% 9 Kit COC 1,500/	5.2% THC 150/50	98.8% THC 0/ 300/	95.7% MPD 1,000 300/
Davidi.	F	96	6.1% AMI 1,00 500	96.1% % Ag P BA 0/ 300 // 20	96.1 reemer R BZ D/ 50 0 30	% 9' t with (O BL 0/ 10 0/ 0/ 0/	7.2% Commo	91. ercial COC 300/	7% 9 Kit COC 1,500/ 200/	5.2% THC 150/50	98.8% THC 0/ 300/ 200/30/	95.7% MPD 1,000 300/
	F	96	AMI 1,00 500 300	96.1% % Ag BA 0/ 300 // 20	96.1 reemer R BZ D/ 50 0 30 20	% 9' tt with (O BU 0/ 10 0/ 0/ 0	7.2% Commo	91. ercial COC 300/ 100	7% 9 Kit COC 1,500/ 200/	5.2% THC 150/50	98.8% THC 300/ 200/30/ 20	95.7% MPD 1,000 300/
Agreement	F	96 ACE ,000	AMI 1,00 500 300	96.1% % Ag BA 0/ 300 // 20	96.1 reemer R BZ D/ 50 0 30 20 10	% 9' tt with (O BU 0/ 10 0/ 0/ 0	7.2% Commo	91. ercial COC 300/ 100	7% 9 Kit COC 1,500/ 200/ 150	5.2% THC 150/50 25	98.8% THC 300/ 200/30/ 20	95.7% MPD 1,000 300/ 150
Agreement Negative	F	96 ACE ,000	AMI 1,00 500 300 >99.8	96.1% % Ag D BA 0/ 300 // 20 0) >9% >99.0	96.1 reemer R BZ D/ 50 0 30 20 10	% 9 It with (O BL 0/ 10 0/ 0/ 0/ 0 9% >99	7.2% Commo	91. ercial COC 300/ 100	7% 9 Kit COC 1,500/ 200/ 150	5.2% THC 150/50 25	98.8% THC 300/ 200/30/ 20 **	95.7% MPD 1,000 300/ 150
Agreement Negative Agreement	5	96 ACE ,,000	5.1% AMI 1,00 500 300 >99.9	96.1% ** Ag ** BA 0/ 300 // 20 9% >99.9 9% >99.9	96.1 reemer R BZ S S S S S S S S	% 9 ***t with (**) O BU 0/ 10 0/ 0/ 0 9% >99 9% >99	7.2% Commodified States 7.2% 7.2	91. ercial COC 300/ 100 99.9%	7% 9 Kit COC 1,500/ 200/ 150 *	5.2% THC 150/50 25 >99.99	98.8% THC 300/ 200/30/ 20 % * * * * * * * * * * * *	95.7% MPD 1,000 300/ 150
Agreement Negative Agreement	5	96 ACE ,000	5.1% AMI 1,00 500 300 >99.9	96.1% ** Ag ** BA 0/ 300 // 20 9% >99.9 9% >99.9	96.1 96.1 10 10 10 10 10 10 10 10	% 9 ***t with (**) O BU 0/ 10 0/ 0/ 0 9% >99 9% >99	7.2% Commodified States 7.2% 7.2	91. ercial COC 300/ 100	7% 9 Kit COC 1,500/ 200/ 150	5.2% THC 150/50 25	98.8% THC 300/ 200/30/ 20 % * * * * * * * * * * * *	95.7% MPD 1,000 300/ 150
Agreement Negative Agreement	f 5	900 ACE ,000	5.1% AMI 1,00 500 300 >99.9 >99.9	96.1% ** Ag ** BA 0/ 300 // 20 9% >99.1 9% >99.1 9% >99.1	96.1 96.1 10 10 10 10 10 10 10	% 9' it with (O BL 0/ 10 0/ 0/ 0/ 9% >99 9% >99 9% >99	7.2% Commodified States 7.2% 7.2	91. ercial COC 300/ 100 99.9% 99.9%	7% 9 Kit COC 1,500/ 200/ 150 * *	5.2% THC 150/50 25 >99.99 >99.99	98.8% THC 300/ 200/30/ 20 * * * * * * * * * * * * *	95.7% MPD 1,000 300/ 150 *
Agreement Negative Agreement	5 Ts	96 ACE ,000	5.1% AMI 1,00 500 300 >99.9 >99.9	96.1% ** Ag ** BA ** 0/ 300 */ 20 ** 300 */ 20 ** 300	96.1 96.1 10 10 10 10 10 10 10 1	% 9 It with (O BL 0/ 10 0/ 0/ 0/ 0 9% > 99 9% > 99 5T MD	7.2% Commodulation 7.2% JP	91. ercial COC 300/ 100 99.9% 99.9%	7% 9 Kit COC 1,500/ 200/ 150 * * MOP/	5.2% THC 150/50 25 >99.99 >99.99 MQL	98.8% THC 300/ 200/30/ 20 * * MEP	95.7% MPD 1,000 300/ 150 * * LSD
Agreement Negative Agreement	7.	96 ACE ,,000 * * *	5.1% AMI 1,00 500 300 >99.9 >99.9 AMI 300	96.1% ** Ag ** BA ** O/ 300 */ 20 ** O/ 99 ** O/ 99 ** O/ ME	96.1 reemer	% 9 It with (O BL 0/ 10 0/ 0/ 0/ 0 9% > 99 9% > 99 9% > 99 T MD 1,0	7.2% Commodified States 7.2% 7.2	91. ercial COC 300/ 100 99.9% 99.9%	7% 9 Kit COC 1,500/ 200/ 150 * * MOP/ OPI	5.2% THC 150/50 25 >99.99 >99.99	98.8% THC 300/ 200/30/ 20 ** * MEP 500/	95.7% MPD 1,000 300/ 150 * * LSD 50/20
Agreement Negative Agreement	ts 7-	96 ACE,,000 * * * *	5.1% AMI 1,00 500 300 >99.9 >99.9 AMI 1,00 500 300 AMI 1,00 500 300 AMI 1,00 500 300	96.1% ** Ag D BA 300 20 9% >99.0 9% >99.0 MED 1,00 500 500 500 **The control of the	96.1 reemer	% 9 It with (O BL 0/ 10 0/ 0/ 0/ 0 9% > 99 9% > 99 9% > 99 T MD 1,0	7.2% Commodulation 7.2% JP	91. ercial COC 300/ 100 99.9% 99.9%	7% 9 Kit COC 1,500/ 200/ 150 * * MOP/ OPI 300/	5.2% THC 150/50 25 >99.99 >99.99 MQL	98.8% THC 300/ 200/30/ 20 * * MEP	95.7% MPD 1,000 300/ 150 * * LSD
Agreement Negative Agreement	ts 7-	96 ACE ,,000 * * *	5.1% AMI 1,00 500 300 >99.9 >99.9 AMI 300	96.1% ** Ag ** BA ** O/ 300 */ 20 ** O/ 99 ** O/ 99 ** O/ ME	96.1 reemer	% 9 It with (O BL 0/ 10 0/ 0/ 0/ 0 9% > 99 9% > 99 9% > 99 T MD 1,0	7.2% Commodified States 7.2% 7.2	91. ercial COC 300/ 100 99.9% 99.9%	7% 9 Kit COC 1,500/ 200/ 150 * * MOP/ OPI 300/ 200/	5.2% THC 150/50 25 >99.99 >99.99 MQL	98.8% THC 300/ 200/30/ 20 ** * MEP 500/	95.7% MPD 1,000 300/ 150 * * LSD 50/20
Agreement Negative Agreement Total Resul	ts 7-	96 ACE ,000 * * * -ACI 800/ 200/ 1100	3.1% AMII 1,000 300 >99.9 >99.9 >90.9 AMII 300 200	96.1% ** Ag D BA 0/ 300 // 20 30% >99.1 D ME 0/ 1,00 30 30 30	96.1 96.1 10 10 10 10 10 10 10	% 9 ***t with (**) **O BL **0/ 0/ **0/ **0/ **0/ **0/ **0/ **0/ *	7.2% Community 9% > 9% > 9% > 9% > 9% > 9% > 9% > 9%	91. Percial COC 300/ 100 99.9% 99.9% IDMA 300	7% 9 Kit COC 1,500/ 200/ 150 * * MOP/ OPI 300/ 200/ 100	THC 150/50 25 >99.99 >99.99 MQL 3000	98.8% THC 300/ 200/30/ 20 % * MEP 500/ 100	95.7% MPD 1,000 300/ 150 * * LSD 50/20 10
Agreement Negative Agreement Total Resul	5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	96 ACE,,000 * * * *	3.1% AMII 1,000 300 >99.9 >99.9 >90.9 AMII 300 200	96.1% ** Ag D BA 300 20 9% >99.0 9% >99.0 MED 1,00 500 500 500 **The control of the	96.1 96.1 10 10 10 10 10 10 10	% 9 ***t with (**) **O BL **0/ 0/ **0/ **0/ **0/ **0/ **0/ **0/ *	7.2% Commodified States 7.2% 7.2	91. ercial COC 300/ 100 99.9% 99.9%	7% 9 Kit COC 1,500/ 200/ 150 * * MOP/ OPI 300/ 200/	THC 150/50 25 >99.99 >99.99 MQL 3000	98.8% THC 300/ 200/30/ 20 % * MEP 500/ 100	95.7% MPD 1,000 300/ 150 * * LSD 50/20
Agreement Negative Agreement Total Resul Positive Agreement	5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	96 ACE,,000 * * * -ACI 800/ 200/ 1100	3.1% AMII 1,000 300 >99.9 >99.9 >90.9 AMII 300 200	96.1% ** Ag D BA 0/ 300 // 20 30% >99.1 D ME 0/ 1,00 30 30 30	96.11 96.11	% 9 9 1t with (O O O O O O O O O O O O O O O O O O O	7.2% Community 9% > 9% > 9% > 9% > 9% > 9% > 9% > 9%	91. 91. 91. 99.9% 99.9% 1DMA 300	7% 9 Kit COC 1,500/ 200/ 150 * * MOP/ OPI 300/ 200/ 100	THC 150/50 25 >99.99 >99.99 MQL 3000	98.8% THC 300/200/30/20 % * MEP 500/100	95.7% MPD 1,000 300/ 150 * * LSD 50/20 10
Positive Agreement Negative Agreement Total Resul Positive Agreement Agreement Agreement	ts 7-3	96 ACE ,000 * * * -ACI 800/ 200/ 1100	3.1% AMM 1,00 500 300 >99.9 >99.9 >99.9 >99.9 >99.9	96.1% ** Ag D BA 0/ 300 // 20 30% >99.1 D ME 0/ 1,00 30 30 30	96.11 96.11	% 9 9 1t with (O D BL) 1C	7.2% Community 9% > 9% > 9% > 9% > 9% > 9% > 9% > 9%	91. Percial COC 300/ 100 99.9% 99.9% IDMA 300	7% 9 Kit COC 1,500/ 200/ 150 * * MOP/ OPI 300/ 200/ 100	THC 150/50, 25 >99.99 >99.99 MQL 300 >99.99	98.8% THC 300/200/30/20 % * MEP 500/100	* * * LSD 50/20 10
Agreement Negative Agreement Total Resul Positive Agreement	ts 7-	96 ACE,,000 * * * -ACI 800/ 200/ 1100	3.1% AMM 1,000 5000 5000 5000 5000 5000 5000 500	96.1% ** Ag BA 300/ 300/ 20 ** Separation Ba Ba Ba Ba Ba Ba Ba Ba Ba B	96.1 reemer R BZ S S S S S S S S S S S S S S S S S S	% 99 11 with 0 O BU 10 O O O O O O O O O O O O O O O O O O	7.2% Communication JP () .9% .	91. 91. 91. 99.9% 99.9% 1DMA 300	7% 9 Kit COC 1,500/ 200/ 150 * MOP/ OPI 300/ 200/ 100 >99.9%	5.2% THC 150/5(_25 >99.99 >99.99 MQL 300 >99.99	98.8% THC 300/200/30/20 % * MEP 500/100	95.7% MPD 1,000 300/ 150 * * LSD 50/20 10

	PPX	TCA	TM	L KE	T C	TC	OPI	PCP	F	CP	DIA	MDPV
	300	1,000	500)/ 1,0	00/ 50	00/ 2	2,000/	50		25	300/	1,000/
		500/	300)/ 50	0/ 30	00/ 1	1,000				200	500/
		300	200)/ 30	0/ 20	00/						300
			100) 10	00 100)/50/						
					1	0						
Positive	>99.99	*	*	>99	00/	*	*	*	٠.	9.9%	*	*
Agreement	>99.97	/0		>99.	.976				29	9.9%		
Negative	>99.99	*	*	>99	00/	*	*	*		9.9%	*	*
Agreement	>99.9%	/o		>99.	.9%				>9	9.9%		
Total Results	>99.99	% *	*	>99	.9%	*	*	*	>9	9.9%	*	*
		•										
	OXY	EDDP	FYL	K2-50/	6-MAM	MDA	ETC	G CLO	Э	ZOL	ZOP	MCAT
	300/	300/	300/	30/25	10	500	1,50	0/ 400)/	50	300/50	500
	100	100	200/		1	1	1 00	0/ 15/	n l			

	OXY	EDDP	FYL	K2-50/	6-MAM	MDA	ETG	CLO	ZOL	ZOP	MCAT
	300/	300/	300/	30/25	10	500	1,500/	400/	50	300/50	500
	100	100	200/				1,000/	150			
			100/20				500/				
			/10				300				
Positive	*	*	*	*	*	*	*	*	*	*	*
Agreement											
Negative	*	*	*	*	*	*	*	*	*	*	*
Agreement											
Total Results	*	*	*	*	*	*	*	*	*	*	*

	CFYL	CAF	CAT	TRO	ALP	PGB	ABP	CNB	TZD	GAB
	500/	1,000	150	350	100	50,000/	10	500	200	2,000
	250					500				
Positive	*	*	*	*	*	*	*	*	*	*
Agreement										
Negative	*	*	*	*	*	*	*	*	*	*
Agreement										
Total Results	*	*	*	*	*	*	*	*	*	*

	CAR	MPRD	QTP	FLX	UR-144	KRA	TLD	α-PVP	MES	ZAL
	2,000/	100	1,000	500	25	300	50	2,000/	100/	100
	1,000/							1,000/	300	
	500							500/		
								300		
Positive	*	*	*	*	*	*	*	*	*	*
Agreement										
Negative	*	*	*	*	*	*	*	*	*	*
Agreement										
Total Results	*	*	*	*	*	*	*	*	*	*

	CIT	FKET	RPD	TAP	NND	SCOP	MTZ	OZP	PAP	HMO
	500	1,000	150	1,000	1,000	500	500	1,000	500	500/
										300/
										250
Positive	*	*	*	*	*	*	*	*	*	*
Agreement										
Negative	*	*	*	*	*	*	*	*	*	*
Agreement										
Total	*	*	*	*	*	*	*	*	*	*
Results										

^{*}Note: Based on GC/MS data instead of Commercial Kit.

Precision

A study was conducted at three hospitals using three different lots of product to demonstrate the within run, between run and between operator precision. An identical card of coded specimens, containing drugs at concentrations of negative, 50% and 25% cut-off level, was labeled, blinded and tested at each site. The results gained ≥75% accuracy in ±25% cut-off level specimen and 100% accuracy in negative and ±50% cut-off level specimen.

Analytical Sensitivity

A drug-free urine pool was spiked with drugs at the listed concentrations. The results are summarized below.

Duis Consontantion	AC	Œ	A۱	ΛP	A۱	ИP	A۱	ИP	BA	٩R	BA	٩R	BZ	ZO	BZ	ZO
Drug Concentration	5,0	000	1,0	000	50	00	30	00	30	00	20	00	50	00	30	00
Cut-off Range	-	+		+	•	+	•	+		+	-	+		+		+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	26	4	26	4	25	5	27	3	27	3	26	4	27	3	27	3
Cut-off	14	16	15	15	15	15	15	15	15	15	15	15	15	15	15	15
+25% Cut-off	3	27	3	27	3	27	4	26	4	26	3	27	4	26	3	27
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30

Drug	BZ	ZO	BZ	ZO	ВІ	JP	ВІ	JP	CC	C	CC	С	CC	C	CC	C	CC	C
Concentration	20	00	10	00	1	0		5	1,5	500	30	00	20	00	15	50	10	00
Cut-off Range	-	+	ı	+	-	+	-	+	-	+	-	+	ı	+	-	+	ı	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	27	3	27	3	26	4	26	4	25	5	26	4	26	4	27	3	27	3
Cut-off	16	14	14	16	14	16	14	16	15	15	13	17	14	16	16	14	16	14
+25% Cut-off	3	27	3	27	3	27	3	27	3	27	3	27	3	27	4	26	4	26
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30

Drug	TH	Ю	TH	НС	TH	НС	М	TD	M	ΤD	MI	ΕT	M	ET	M	ΞT	M	ΕT
Concentration	1	50	5	0	2	5	30	00	20	00	1,0	000	50	00	30	00	20	00
Cut-off Range	-	+	•	+	-	+	-	+	ı	+	ı	+	ı	+	ı	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	27	3	26	4	27	3	27	3	27	3	27	3	27	3	27	3	27	3
Cut-off	15	15	14	16	15	15	13	17	15	15	16	14	15	15	16	14	15	15
+25% Cut-off	4	26	3	27	4	26	4	26	4	26	3	27	4	26	3	27	4	26
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30

Drug Concentration Cut-off Range	MD 1,0	MA 000		MA 00	MC O 30		0	DP/ PI D0	O 2,0	PI 000	P0 5		P(PF 30	PX 00
	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	26	4	25	5	26	4	26	4	27	3	26	4	25	5	26	4
Cut-off	15	15	14	16	15	15	15	15	15	15	15	15	15	15	14	16
+25% Cut-off	5	25	4	26	3	27	3	27	5	25	3	27	3	27	3	27
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30

Drug	TN	ЛL	TN	ЛL	TN	ЛL	TN	ЛL	K	ΞT	KE	ΞT	K	ΞT	K	ΞT	M	QL
Concentration	10	00	20	00	30	00	50	00	1,0	000	50	00	30	00	10	00	30	00
Cut-off Range	•	+	•	+	•	+	•	+	•	+	•	+	•	+	•	+	•	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	27	3	27	3	27	3	26	4	27	3	27	3	26	4	27	3	27	3
Cut-off	15	15	15	15	15	15	14	16	16	14	15	15	15	15	15	15	15	15
+25% Cut-off	4	26	4	26	4	26	3	27	3	27	4	26	4	26	3	27	4	26
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30

Drug Concentration	0)	XY 00	O)	XY 00	C(OT 00	C(OT 00		DP 00		DP 00	F` 2	YL 0	F\ 1	_
Cut-off Range	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	27	3	27	3	27	3	27	з	27	З	26	4	27	3	27	3
Cut-off	15	15	15	15	15	15	14	16	15	15	15	15	14	16	15	15

+25% Cut-o	ff	4	26	6 4		26	4	26	4	26	6	4 :	26	3	27	7	4 :	26	3	2
+50% Cut-o	ff	0	30	0) 3	0	0	30	0	30)) :	30	0	30)	0 :	30	0	3
+300% Cut-c	off	0	30	0 0) 3	0	0	30	0	30)) :	30	0	30)	0 :	30	0	3
Drug		K2	ŀ	(2	6-N	1AM	ΙМ	DA	E.	ΓG	E.	ΓG	ΕΊ	G	С	LO	С	LO	LS	SE
Concentration		50		30	1	0		00		00		00	1,0		_	00	1	50		20
Cut-off Range	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	T-	+	-	Ĺ
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	1
-50% Cut-off	30	0 (30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	1
-25% Cut-off	26	6 4	27	3	27	3	26	4	25	5	26	4	26	4	26	4	26	4	27	1
Cut-off	15	15	16	14	15	15	15	15	16	14	15	15	15	15	14	16	14	16	14	1
+25% Cut-off	3	27	4	26	4	26	3	27	4	26	3	27	3	27	5	25	5	25	3	2
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	3
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	3
																				•
			_ [70				_		М	IOP/	١.	450			_	MD	D\ /		
Drug		LSI		ZO			MA		HC	(OPI		MEP		ME		MD		ET	
Concentration		50	'	50	,	31	00	2	00	2	200		500		100	U	1,0	00	1,5	οU
Cut-off Range	_ [-	+	-	+	-	+	-	+	<u> </u>	+] -	+		-	+	-	+	-	
0% Cut-off		30	0	30	0	30	0	30	0	30	0	30) (3	30	0	30	0	30	
-50% Cut-off		30	0	30	0	30	0	30	0	30	0	30	0 0	3	30	0	30	0	30	
-25% Cut-off		27	3	26	4	25	5	26	4	26	4	27	7 3	2	27	3	26	4	27	
Cut-off		14	16	14	16	15	15	15	15	15	15	5 15	5 1	5 1	7	13	14	16	15	ŀ
+25% Cut-off		3	27	5	25	3	27	4	26	4	26	6 4	2	3	5 2	25	3	27	3	:
+50% Cut-off		0	30	0	30	0	30	0	30	0	30	0	3)	0 ;	30	0	30	0	.;
+300% Cut-of	f	0	30	0	30	0	30	0	30	0	30	0	3)	0 ;	30	0	30	0	.;
Drug	MD	PV	MDI	Pγ	DI	4	DI	Α	TH	С	TH	С	K:	2	ZC	OP	Z	OP	MC	C/
Concentration	50	00	30	0	30	0	20	0	30	0	30)	2	5	30	00	_ 5	50	50	0(
Cut-off Range	-	+	-	+	-	+	-	+	-	+	-	+	-	+	_	+	<u> </u>	+	L-	
0% Cut-off	30	0	30	0 ;	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	Ī
-50% Cut-off	30	0	30	0 ;	30	0	29	1	30	0	30	0	30	0	30	0	30	0	30	
-25% Cut-off	25	5	26	4 :	27	3	27	3	26	4	26	4	25	5	28	2	27	3	28	
Cut-off	15	15	14	16	15	15	15	15	15	15	14	16	14	16	17	13	17	13	17	1
+25% Cut-off	3	27	3	27	3 :	27	3	27	4	26	4	26	3	27	3	27	4	26	3	2
+50% Cut-off	0	30	0	30	0	30	1	29	0	30	0	30	0	30	0	30	0	30	0	9
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	3
Drive	7	ACL	7	ACL	7	-AC	, T	CF)	/ ₁ T	C/	\E	_	AT	Τ.	TRC	, 1	AL	ь	α-P)\ A
Drug Concentration		4CL 00		ACL 200		-AC 100		50		1,0		_	50		350		10		1,0	
Cut-off Range	-	1+	-	1+	_	-	+	-	+	- 1,0	+	-	+	Τ.		+	_ [+	-	
0% Cut-off	30	0	30	+-	30	+		30	0	30	0	30	+-	3	-	0	30	0	30	۰
-50% Cut-off	30	0	30	+-	_	_	_	30	0	30	0	30	+-	3	_	0	30	0	30	ŀ
-25% Cut-off	26	4	27	_	-	_	_	30 25	5	26	4	27	3	2	_	3	28	2	26	t
Cut-off	14	16	14	_	-	_	_	_	16	17	13	17	13	_	_	3 15	17	13	15	
+25% Cut-off	5	25	3	27	_	_	_	_	24	6	24	4	26	_	_	27	3	27	3	2
+50% Cut-off	0	30	0	30	-	_	_	_	30	0	30	0	30	_	_	30	0	30	0	1
+30% Cut-off	0	30	0	30	_	_	10	_	30	0	30	0	30	_	_	30	0	30	0	0
. 20070 Out OII		100		100				-	55		55		100		. -	· •	ŭ	55	J	
Drug	F	YL	CC	т	TC	A:	т	CA	TC	A.	0	ы	TH	IC	C	AR	C	AR	C	ДΙ
Concentration	ı	00	30		1,0			00	30		1,0		2			000		000	50	
Cut-off Range	-	+	-	+	-	+	-	+	-	+	-	+	- Ī	+	-,	+	-	+	-	Ĭ
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	-	30	_	30	t
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30		30		30	+
-25% Cut-off	27	3	25	5	25	5	26	4	27	3	27	3	26	4	28		27	3	27	t
Cut-off	15	15	15	15	15	15	14	16	14	16	14	16	14	16	16		_	_	15	٠
	3	27	4	26	4	26	3	27	3	27	4	26	4	26	3	27	_	26	4	1
					0	30	0	30	0	30	0	30	0	30	0	30	_	30	0	:
+25% Cut-off	n	30	()	301																
	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	_	30	0	:

Drug			PD		ИРC)	MF			GB			βB	_	AB	1	TZI			NB	:	PA	
Concentration		1:	50	<u> </u>	300	4	1,0	00		000)	50	00	- 1	000	4	200)	5	00	4	50	00
Cut-off Rang	je	-	+	<u>↓-</u>	+	_	-	+	-	+	+	-	+	-	+	-	_	+	-	+	_	-	+
0% Cut-off		30	0	30	_	_	30	0	30	0	+	30	0	30	_	3	-	0	30	()	30	0
-50% Cut-of	_	30	0	30	_	_	30	0	30	0	_	30	0	30	_	3	_	0	30	(-	30	0
-25% Cut-of	ff	26	4	27	_	_	26	4	25	5	_	25	5	28	+-	2	_	2	27	+	-	29	1
Cut-off		15	15	16	_	_	16	14	15	15	-	15	15	14	_	_	_	16	14	-	6	15	15
+25% Cut-o	_	5	25	5	2	-	5	25	5	25	-	6	24	3	27	_	_	27	4	2	-	1	29
+50% Cut-o	_	0	30	0	3	-	0	30	0	30	-	0	30	0	30	_	_	30	0	3	-	0	30
+300% Cut-0	off	0	30	0	3	0	0	30	0	30)	0	30	0	30	() (30	0	3	0	0	30
Drug		AB	Р	QT	Р	FI	_X	K	RA	1	ГЦС)	α-P	VP	α-P	VΡ	α-F	PVF	ŀ	S)	ΗN	ΛО
Concentratio	n	10)	1,0	00	50	00	3	00		50		2,0	00	50	0	3	00		10	1	50	00
Cut-off Rang	е	-	+	-	+	-	+	-	+	-		+	-	+	-	+	-	+	-	T	+	-	+
0% Cut-off	- ;	30	0	30	0	30	0	30	0	30) (0	30	0	30	0	30	0	30)	0	30	0
-50% Cut-of	f :	30	0	30	0	30	0	30	0	30) (0	30	0	30	0	30	0	30)	0	30	0
-25% Cut-of	f 2	25	5	29	1	29	1	28	2	29	9	1	26	4	27	3	27	3	27	7	3	28	2
Cut-off		15	15	15	15	15	15	14	16	15	5 1	5	15	15	15	15	15	15	14	1 1	16	15	15
+25% Cut-of	f	4	26	1	29	2	28	1	29	1	2	29	3	27	3	27	3	27	3	- 2	27	3	27
+50% Cut-of	f	0	30	0	30	0	30	0	30	0	3	30	0	30	0	30	0	30	0	- 3	30	0	30
+300% Cut-o	ff	0	30	0	30	0	30	0	30	0	3	30	0	30	0	30	0	30	0	- 3	30	0	30
Drug	CC	тс	CC	т	CC	т	CF	ΥL	F١	/L	Z	ZAL	М	PRI	т	ΆP		CIT		-KI	ET	F,	YL
Concentration	50	00	5	0	1	0	25	50	20	00	1	100		100	1,	000) .	500	, -	1,0	00	30	00
Cut-off Range	- 1	+	- 1	+	-	+	_	+	_	+	١.	Т	. -	+	+	+	۲.		-	_	+	 	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	-	_	_	-	-	3	-	-+	80	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	_	-	-		_	_	_	-	80	0	30	0
-25% Cut-off	26	4	27	3	27	3	25	5	27	3	27	_	_	_	_	_	-	_		27	3	27	3
Cut-off	14	16	16	14	15	15	14	16	15	15	15	_	_	_	_	_	_	_	-	_	15	17	13
+25% Cut-off	3	27	4	26	4	26	6	24	3	27	4	-	_	-		26		· ·	~ .	Ť	27	4	26
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	푸	_	_	_	30	_	_		_	30	0	30
+300%	0	30	0	30	0	30	0	30	0	30	0	Ť	Ť			30	T	Ť	Ť		30	0	30
Cut-off	U	30	U	30	U	30	U	30	U	30	U	٦	٦	, 3	9	30		, 3	٠,	J	30	U	30
-																							
Drug		R	PD	sc	OF	٨١	IND	١,	ИΤΖ	.	ΟZ	'P	М	ES	M	S	_	JR-	١,	нм	0	н	<i>1</i> 0
Concentration	าท	1	50		00	1 -	,000	1 -	500		1,0			00		00		44	1 -	25	-		00
Cut-off Rand		Ŀ				Ļ		4		4	.,5		Ľ	_	Ľ		Ľ	25	4	_		- 50	
	_	-	+	-	+	ŀ	+	_	+	-	-	+	-	+	-	+	<u> -</u>	+	-	-	+	-	+
0% Cut-of		30	-	30	+-	30	_	_	_	-	0	0	30	0	30	0	30	_		-	0	30	0
	ff	30	0	30	0	30	0 (30	0 0) [3	80	0	30	0	30	0	30	0	3	0	0	30	0
-50% Cut-o		T		1.						- 1		_								. T			
-50% Cut-o -25% Cut-o Cut-off	ff	27 15	3 15	26 14	4 16	27	_	_	_	_	7 4	3 16	27 14	3 16	27 14	3 16	28 15	+	-	_	2 15	28 15	2 15

Drug Concentration Cut-off Range		PD 50		00 00)00 ND		00	1,0	2P 000		-S 00		-S 00		44 5		лО 50	30	ЛО 00
Cut-on Range	-	+	-	+	-	+	-	+	-	+	-	+	ı	+	-	+	ı	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	27	3	26	4	27	3	27	3	27	3	27	3	27	3	28	2	28	2	28	2
Cut-off	15	15	14	16	15	15	15	15	14	16	14	16	14	16	15	15	15	15	15	1
+25% Cut-off	4	26	3	27	4	26	4	26	4	26	5	25	4	26	3	27	3	27	2	2
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	3
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	3
						•		- 1 0		161 - 1										

Analytical Specificity

The following table lists the concentrations of compounds (ng/mL) that are detected as positive in urine by the Multi-Drug Rapid Test at 5 minutes.

Analytes	conc. (ng/m	nL) Analytes	conc. (ng/mL)
	ACETAMINO	PHEN (ACE 5,000)	
Acetaminophen	5,000		
	AMPHETAM	INE (AMP 1,000)	
D,L-Amphetamine sulfate	300	Phentermine	1,000
L-Amphetamine	25,000	Maprotiline	50,000
(±) 3,4-Methylenedioxy	500	Methoxyphenamine	6,000
amphetamine	500	D-Amphetamine	1,000
	AMPHETAN	MINE (AMP 500)	
D,L-Amphetamine sulfate	150	Phentermine	500
L-Amphetamine	12,500	Maprotiline	25,000
(±) 3,4-Methylenedioxy	250	Methoxyphenamine	3,000
amphetamine	230	D-Amphetamine	500
	AMPHETAN	MINE (AMP 300)	

D,L-Amphetamine sulfate	75	Phentermine	300
L-Amphetamine	10,000	Maprotiline	15,000
(±) 3,4-Methylenedioxy	450	Methoxyphenamine	2,000
amphetamine	150	D-Amphetamine	300
	BARBITURAT	ES (BAR 300)	
Amobarbital	5,000	Alphenol	600
5,5-Diphenylhydantoin	8,000	Aprobarbital	500
Allobarbital	600	Butabarbital	200
Barbital	8,000	Butalbital	8,000
Talbutal	200	Butethal	500
Cyclopentobarbital	30,000	Phenobarbital	300
Pentobarbital	8,000	Secobarbital	300
	BARBITURAT	TES (BAR 200)	
Amobarbital	3,000	Alphenol	400
5,5-Diphenylhydantoin	5,000	Aprobarbital	300
Allobarbital	400	Butabarbital	150
Barbital	5,000	Butalbital	5,000
Talbutal	150	Butethal	300
Cyclopentobarbital	20,000	Phenobarbital	200
Pentobarbital	5,000	Secobarbital	200
	BENZODIAZEP	INES (BZO 500)	•
Alprazolam	200	Bromazepam	1,500
a-hydroxyalprazolam	2,500	Chlordiazepoxide	1,500
Clobazam	300	Nitrazepam	300
Clonazepam	800	Norchlordiazepoxide	200
Clorazepatedipotassium	800	Nordiazepam	1,500
Delorazepam	1,500	Oxazepam	500
Desalkylflurazepam	300	Temazepam	300
Flunitrazepam	300	Diazepam	500
(±) Lorazepam	5,000	Estazolam	10,000
RS-Lorazepamglucuronide	300	Triazolam	5,000
Midazolam	10,000		
	BENZODIAZEP	INES (BZO 300)	
Alprazolam	100	Bromazepam	900
a-hydroxyalprazolam	1,500	Chlordiazepoxide	900
Clobazam	200	Nitrazepam	200
Clonazepam	500	Norchlordiazepoxide	100
Clorazepatedipotassium	500	Nordiazepam	900
Delorazepam	900	Oxazepam	300
Desalkylflurazepam	200	Temazepam	100
Flunitrazepam	200	Diazepam	300
(±) Lorazepam	3,000	Estazolam	6,000
RS-Lorazepamglucuronide	200	Triazolam	3,000
Midazolam	6,000		
	BENZODIAZEP	INES (BZO 200)	
Alprazolam	70	Bromazepam	600
a-hydroxyalprazolam	1,000	Chlordiazepoxide	600
Clobazam	120	Nitrazepam	120
Clonazepam	300	Norchlordiazepoxide	70
Clorazepatedipotassium	300	Nordiazepam	600
Delorazepam	600	Oxazepam	200
Desalkylflurazepam	000		
	120	Temazepam	70
Flunitrazepam	120		
	120 120	Diazepam	70 200 4,000
(±) Lorazepam	120		200
Flunitrazepam (±) Lorazepam RS-Lorazepamglucuronide Midazolam	120 120 2,000	Diazepam Estazolam	200 4,000
(±) Lorazepam RS-Lorazepamglucuronide	120 120 2,000 120 4,000	Diazepam Estazolam Triazolam	200 4,000
(±) Lorazepam RS-Lorazepamglucuronide Midazolam	120 120 2,000 120 4,000 BENZODIAZEP	Diazepam Estazolam Triazolam INES (BZO 100)	200 4,000 2,000
(±) Lorazepam RS-Lorazepamglucuronide Midazolam Alprazolam	120 120 2,000 120 4,000 BENZODIAZEP 40	Diazepam Estazolam Triazolam INES (BZO 100) Bromazepam	200 4,000 2,000
(±) Lorazepam RS-Lorazepamglucuronide Midazolam Alprazolam a-hydroxyalprazolam	120 120 2,000 120 4,000 BENZODIAZEP 40 500	Diazepam Estazolam Triazolam INES (BZO 100) Bromazepam Chlordiazepoxide	200 4,000 2,000 300 300
(±) Lorazepam RS-Lorazepamglucuronide Midazolam Alprazolam a-hydroxyalprazolam Clobazam	120 120 2,000 120 4,000 BENZODIAZEP 40 500 60	Diazepam Estazolam Triazolam INES (BZO 100) Bromazepam Chlordiazepoxide Nitrazepam	200 4,000 2,000 300 300 60
(±) Lorazepam RS-Lorazepamglucuronide Midazolam Alprazolam a-hydroxyalprazolam	120 120 2,000 120 4,000 BENZODIAZEP 40 500	Diazepam Estazolam Triazolam INES (BZO 100) Bromazepam Chlordiazepoxide	200 4,000 2,000 300 300

h .	000	lo .	400
Delorazepam	300	Oxazepam	100
Desalkylflurazepam	60	Temazepam	40
Flunitrazepam	60	Diazepam	100
(±) Lorazepam	1,000	Estazolam	2,000
RS-Lorazepamglucuronide	60	Triazolam	1,000
Midazolam	2,000	NE (BUB 40)	1
	BUPRENORPHI		ls o
Buprenorphine	10	Norbuprenorphine	50
Buprenorphine 3-D-Glucuronide	50	Norbuprenorphine 3-D-Glucuronide	100
	BUPRENORPH		
Buprenorphine	5	Norbuprenorphine	25
	5	Norbuprenorphine	23
Buprenorphine 3-D-Glucuronide	25	3-D-Glucuronide	50
	COCAINE (CO		1
Benzoylecgonine	1,500	Cocaethylene	100,000
Cocaine HCI	1200	Ecgonine	150,000
	COCAINE (C	•	1.00,000
Benzoylecgonine	300	Cocaethylene	20,000
Cocaine HCI	200	Ecgonine	30,000
	COCAINE (C		
Benzoylecgonine	200	Cocaethylene	13,500
Cocaine HCI	135	Ecgonine	20,000
	COCAINE (C		
Benzoylecgonine	150	Cocaethylene	10,000
Cocaine HCI	120	Ecgonine	15,000
	COCAINE (C		
Benzoylecgonine	100	Cocaethylene	7,000
Cocaine HCI	80	Ecgonine	10,000
	MARIJUANA		
Cannabinol	200,000	∆ ⁸ -THC	100,000
11-nor-△ ⁸ -THC-9 COOH	200	∆ ⁹ -THC	100,000
11-nor-△ ⁹ -THC-9 COOH	300		
	MARIJUANA	(THC 200)	•
Cannabinol	140,000	∆ ⁸ -THC	68,000
11-nor-△ ⁸ -THC-9 COOH	120	∆ ⁹ -THC	68,000
11-nor-∆ ⁹ -THC-9 COOH	200		
	MARIJUANA		
Cannabinol	100,000	∆ ⁸ -THC	50,000
11-nor-∆ ⁸ -THC-9 COOH	100	∆ ⁹ -THC	50,000
11-nor-∆ ⁹ -THC-9 COOH	150		
	MARIJUANA		
Cannabinol	35,000	Δ ⁸ -THC	17,000
11-nor- Δ^8 -THC-9 COOH	30	Δ ⁹ -THC	17,000
11-nor-△ ⁹ -THC-9 COOH	50		1
	MARIJUANA		
Cannabinol	20,000	Δ ⁸ -THC	10,000
11-nor-Δ ⁸ -THC-9 COOH	20	∆ ⁹ -THC	10,000
11-nor-Δ ⁹ -THC-9 COOH	30		1
	MARIJUANA		_
Cannabinol	17,500	∆ ⁸ -THC	8,500
11-nor- Δ^8 -THC-9 COOH	15	△ ⁹ -THC	8,500
11-nor-△9-THC-9 COOH	25		1
	MARIJUANA		T
Cannabinol	14,000	△ ⁸ -THC	6,800
11-nor- Δ^8 -THC-9 COOH	12	△ ⁹ -THC	6,800
11-nor-△ ⁹ -THC-9 COOH	20	(1170,000)	1
• • • •	METHADONE	· · · · · · · · · · · · · · · · · · ·	400.00-
Methadone	300	Doxylamine	100,000
Made alexan	METHADONE	· · · · · · · · · · · · · · · · · · ·	05.000
Methadone	200	Doxylamine	65,000
	THAMPHETAMII		I
ρ-Hydroxymethamphetamine	25,000	(±)-3,4-Methylenedioxy-	12,500

		T	
D-Methamphetamine	1,000	methamphetamine	
L-Methamphetamine	20,000	Mephentermine	50,000
		AMINE (MET 500)	
ρ-Hydroxymethamphetamine	12,500	(±)-3,4-Methylenedioxy-	6,250
D-Methamphetamine	500	methamphetamine	0,200
L-Methamphetamine	10,000	Mephentermine	25,000
		AMINE (MET 300)	
ρ-Hydroxymethamphetamine	7,500	(±)-3,4-Methylenedioxy-	3,750
D-Methamphetamine	300	methamphetamine	
L-Methamphetamine	6,000	Mephentermine	15,000
		AMINE (MET 200)	
ρ-Hydroxymethamphetamine	5,000	(±)-3,4-Methylenedioxy-	2,500
D-Methamphetamine	200	methamphetamine	40.000
L-Methamphetamine	4,000	Mephentermine	10,000
	T HAMPH	ETAMINE (MDMA 1, 000) Ecs	stasy
(±) 3,4-Methylenedioxy-	1,000	3,4-Methylenedioxyethyl-	600
methamphetamine HCI	.	amphetamine	
(±) 3,4-Methylenedioxyamphetamine HCl	6,000		
	XYMETHAMD	 HETAMINE (MDMA 500) Ecst	asv
(±) 3,4-Methylenedioxy-		3,4-Methylenedioxyethyl-	
methamphetamine HCl	500	amphetamine	300
(±) 3,4-Methylenedioxyampheta	. 1		1
mine HCI	3,000		
	XYMETHAMP	HETAMINE (MDMA 300) Ecst	asv
(±) 3,4-Methylenedioxy-		3,4-Methylenedioxyethyl-	
methamphetamine HCI	300	amphetamine	180
(±) 3,4-Methylenedioxyampheta	4 000		
mine HCI	1,800		
	MORPHINE (MOP/OPI 300)	
Codeine	200	Norcodeine	6,000
Levorphanol	1,500	Normorphone	50,000
Morphine-3-β-D-Glucuronide	800	Oxycodone	30,000
Ethylmorphine	6,000	Oxymorphone	50,000
Hydrocodone	50,000	Procaine	15,000
Hydromorphone	3,000	Thebaine	6,000
6-Monoacethylmorphine	300	Morphine	300
	MORPHINE (MOP/OPI 200)	
Codeine	160	Norcodeine	4,000
Levorphanol	1,000	Normorphone	40,000
Morphine-3-β-D-Glucuronide	600	Oxycodone	20,000
Ethylmorphine	4,000	Oxymorphone	40,000
Hydrocodone	40,000	Procaine	10,000
Hydromorphone	2,000	Thebaine	4,000
6-Monoacethylmorphine	200	Morphine	200
		MOP/OPI 100)	
Codeine	80	Norcodeine	2,000
Levorphanol	500	Normorphone	20,000
Morphine-3-β-D-Glucuronide	300	Oxycodone	10,000
Ethylmorphine	2,000	Oxymorphone	20,000
Hydrocodone	20,000	Procaine	5,000
Hydromorphone	1,000	Thebaine	2,000
6-Monoacethylmorphine	200	Morphine	100
		ONE (MQL 300)	1
Methaqualone	300	LATE (ODI O OCE)	
		IATE (OPI 2,000)	la ann
Codeine	2,000 3,000	Morphine	2,000
Ethylmorphine	12 (1/1/1)	Norcodeine	25,000
Ularada e e aderea e		Managara Ing.	
Hydrocodone	50,000	Normorphone	50,000
Hydromorphone	50,000 15,000	Oxycodone	25,000
Hydromorphone Levorphanol	50,000 15,000 25,000	Oxycodone Oxymorphone	25,000 25,000
Hydromorphone	50,000 15,000	Oxycodone	25,000

	MORPHINE/OI	PIATE (OPI 1,000)	
Codeine	1,000	Morphine	1,000
Ethylmorphine	1,500	Norcodeine	12,500
Hydrocodone	25,000	Normorphone	25,000
Hydromorphone	7,500	Oxycodone	12,500
Levorphanol	12,500	Oxymorphone	12,500
6-Monoacetylmorphine	1,500	Procaine	25,000
Morphine 3-β-D-glucuronide	1,000	Thebaine	12,500
	MEPERIDIN	IE (MPRD 100)	
Normeperidine	100	Meperidine	100
	PHENCYCL	IDINE (PCP 50)	
Phencyclidine	50	4-Hydroxyphencyclidine	25,000
	PHENCYCL	IDINE (PCP 25)	
Phencyclidine	25	4-Hydroxyphencyclidine	12,500
	PROPOXYPI	IENE (PPX 300)	
D-Propoxyphene	300	D-Norpropoxyphene	300
TRIC	YCLIC ANTIDEP	RESSANTS (TCA 1,000)	
Nortriptyline	1,000	Imipramine	400
Nordoxepine	500	Clomipramine	50,000
Trimipramine	3,000	Doxepine	2,000
Amitriptyline	1,500	Maprotiline	2,000
Promazine	3,000	Promethazine	50,000
Desipramine	200	Perphenazine	50,000
Cyclobenzaprine	2,000	Dithiaden	10,000
TRIC	CYCLIC ANTIDE	PRESSANTS (TCA 500)	
Nortriptyline	500	Imipramine	200
Nordoxepine	250	Clomipramine	25,000
Trimipramine	1,500	Doxepine	1,000
Amitriptyline	750	Maprotiline	1,000
Promazine	1,500	Promethazine	25,000
Desipramine	100	Perphenazine	25,000
Cyclobenzaprine	1,000	Dithiaden	5,000
TRIC	CYCLIC ANTIDE	PRESSANTS (TCA 300)	
Nortriptyline	300	Imipramine	120
Nordoxepine	150	Clomipramine	15,000
Trimipramine	900	Doxepine	600
Amitriptyline	450	Maprotiline	600
Promazine	900	Promethazine	15,000
Desipramine	60	Perphenazine	15,000
Cyclobenzaprine	600	Dithiaden	3,000
	TDAMAD	(=====	
	IRAMADO	OL (TML 100)	
n-Desmethyl-cis-tramadol	200	o-Desmethyl-cis-tramadol	10,000
n-Desmethyl-cis-tramadol Cis-tramadol	1	<u> </u>	10,000
•	200	o-Desmethyl-cis-tramadol	100,000
Cis-tramadol	200 100 100,000	o-Desmethyl-cis-tramadol Phencyclidine	100,000
Cis-tramadol	200 100 100,000	o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine	100,000
Cis-tramadol Procyclidine	200 100 100,000 TRAMADO	o-Desmethyl-cis-tramadol Phencyclidine d,I-O-Desmethyl venlafaxine DL (TML 200)	100,000 50,000
Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol	200 100 100,000 TRAMADO 400	o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 200) o-Desmethyl-cis-tramadol	100,000 50,000 20,000 200,000
Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol	200 100 100,000 TRAMADO 400 200 200,000	o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 200) o-Desmethyl-cis-tramadol Phencyclidine	100,000 50,000 20,000 200,000
Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol	200 100 100,000 TRAMADO 400 200 200,000 TRAMADO	o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 200) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine	100,000 50,000 20,000 200,000
Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine	200 100 100,000 TRAMADO 400 200 200,000	o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 200) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 300)	100,000 50,000 20,000 200,000 100,000
Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol	200 100 100,000 TRAMADO 400 200 200,000 TRAMADO	o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 200) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 300) o-Desmethyl-cis-tramadol	100,000 50,000 20,000 200,000 100,000
Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol	200 100,000 TRAMADO 400 200 200,000 TRAMADO 600 300 300,000	o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 200) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 300) o-Desmethyl-cis-tramadol Phencyclidine	100,000 50,000 20,000 200,000 100,000 30,000 300,000
Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine	200 100,000 TRAMADO 400 200 200,000 TRAMADO 600 300 300,000	o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 200) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 300) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 500)	100,000 50,000 20,000 200,000 100,000 30,000 300,000
Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine	200 100,000 TRAMADO 200 200,000 TRAMADO 600 300 300,000 TRAMADO	o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 200) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 300) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine	100,000 50,000 20,000 200,000 100,000 30,000 300,000 150,000
Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine Procyclidine	200 100 100,000 TRAMADO 200 200,000 TRAMADO 600 300 300,000 TRAMADO 10,000	o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 200) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 300) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 500) o-Desmethyl-cis-tramadol Phencyclidine DL (TML 500) p-Desmethyl-cis-tramadol Phencyclidine	100,000 50,000 20,000 200,000 100,000 30,000 150,000 50,000
Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Cis-tramadol Cis-tramadol	200 100 100,000 TRAMADO 200 200,000 TRAMADO 600 300 300,000 TRAMADO 10,00 500 500,000	o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 200) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 300) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 500) o-Desmethyl-cis-tramadol	100,000 50,000 20,000 200,000 100,000 30,000 150,000 50,000 500,000
Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine	200 100 100,000 TRAMADO 200 200,000 TRAMADO 600 300 300,000 TRAMADO 10,00 500 500,000 KETAMINE	o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 200) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 300) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 500) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine E(KET 1, 000)	100,000 50,000 20,000 200,000 100,000 30,000 300,000 150,000 50,000 500,000 250,000
Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine Ketamine	200 100,000 TRAMADO 200 200,000 TRAMADO 600 300 300,000 TRAMADO 10,000 500 500 500,000 KETAMINE	o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 200) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 300) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 500) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 500) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine E(KET 1, 000) Benzphetamine	100,000 50,000 200,000 200,000 100,000 300,000 150,000 500,000 250,000 250,000
Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Ketamine Dextromethorphan	200 100,000 TRAMADO 400 200 200,000 TRAMADO 600 300 300,000 TRAMADO 10,000 500 500,000 KETAMINE 1,000 2,000	o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 200) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 300) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 500) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine E (KET 1, 000) Benzphetamine (+) Chlorpheniramine	100,000 50,000 20,000 200,000 100,000 30,000 300,000 150,000 500,000 250,000 25,000 25,000
Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol Procyclidine n-Desmethyl-cis-tramadol Cis-tramadol	200 100,000 TRAMADO 200 200,000 TRAMADO 600 300 300,000 TRAMADO 10,000 500 500 500,000 KETAMINE	o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 200) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 300) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 500) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine DL (TML 500) o-Desmethyl-cis-tramadol Phencyclidine d,l-O-Desmethyl venlafaxine E(KET 1, 000) Benzphetamine	100,000 50,000 200,000 200,000 100,000 300,000 150,000 500,000 250,000 250,000

Dromoth oning	OF 000	Lavounhanal	E0 000
Promethazine	25,000	Levorphanol	50,000
Pentazocine	25,000	MDE	50,000
Phencyclidine	25,000	Meperidine	25,000
Tetrahydrozoline	500	d-Methamphetamine	50,000
Mephentermine	25,000	I-Methamphetamine	50,000
(1R, 2S) - (-)-Ephedrine	100,000	3,4-Methylendioxymetham- phetamine (MDMA)	100,000
Disopyramide	25,000	Thioridazine	50,000
. ,	KETAMINE (I	KET 500)	•
Ketamine		Benzphetamine	12,500
Dextromethorphan	1,000	(+) Chlorpheniramine	12,500
Methoxyphenamine	12,500	Clonidine	50,000
d-Norpropoxyphene	12,500	EDDP	25,000
Promazine	12,500	4-Hydroxyphencyclidine	25,000
Promethazine	12,500	Levorphanol	25,000
	12,500	MDE	
Pentazocine			25,000
Phencyclidine	12,500	Meperidine	12,500
Tetrahydrozoline	250	d-Methamphetamine	25,000
Mephentermine	12,500	I-Methamphetamine	25,000
(1R, 2S) - (-)-Ephedrine	50,000	3,4-Methylendioxymetham- phetamine (MDMA)	50,000
Disopyramide	12,500	Thioridazine	25,000
Disopyramide			25,000
Votomino	KETAMINE (I	, , , , , , , , , , , , , , , , , , ,	6 250
Ketamine		Benzphetamine	6,250
Dextromethorphan	600	(+) Chlorpheniramine	6,250
Methoxyphenamine	6,250	Clonidine	30,000
d-Norpropoxyphene	6,250	EDDP	15,000
Promazine	6,250	4-Hydroxyphencyclidine	15,000
Promethazine	6,250	Levorphanol	15,000
Pentazocine	6,250	MDE	15,000
Phencyclidine	6,250	Meperidine	6,250
Tetrahydrozoline	150	d-Methamphetamine	15,000
Mephentermine	6,250	I-Methamphetamine	15,000
(1R, 2S) - (-)-Ephedrine	30,000	3,4-Methylendioxymetham- phetamine (MDMA)	30,000
Disopyramide	6,250	Thioridazine	15,000
	KETAMINE (I	KET 100)	
Ketamine	100	Benzphetamine	2,000
Dextromethorphan	200	(+) Chlorpheniramine	2,000
Methoxyphenamine	2,000	Clonidine	10,000
d-Norpropoxyphene	2,000	EDDP	5,000
Promazine	2,000		5,000
		4-Hydroxyphencyclidine	
Promethazine	2,000	Levorphanol	5,000
Pentazocine Disagrapiation	2,000	MDE	5,000
Phencyclidine	2,000	Meperidine	2,000
Tetrahydrozoline	50	d-Methamphetamine	5,000
Mephentermine	2,000	I-Methamphetamine	5,000
(1R, 2S) - (-)-Ephedrine	10,000	Thioridazine	5,000
Disopyramide	2,000	3,4-Methylendioxymetham- phetamine (MDMA)	10,000
	OXYCODONE		•
Oxycodone	300	Hydromorphone	150,000
Oxymorphone	900	Naloxone	75,000
Levorphanol	15,000	Naltrexone	75,000
Hydrocodone	75,000		. 5,000
i iyarooddiib	OXYCODONE	(OXY 100)	<u> </u>
Oxycodone	100	Hydromorphone	50,000
Oxymorphone	300	Naloxone	25,000
Levorphanol	50,000	Naltrexone	25,000
Hydrocodone	25,000		_5,000
i iyaroodanie	COTININE (C	OT 300)	I
(-)-Cotinine	300	(-)-Nicotine	7,500
(-)-Commie			,300
	COTININE (C	O 1 200)	

(-)-Cotinine	200	(-)-Nicotine	5,000
() 0 ::	COTININE	· , · · · · · · · · · · · · · · · · · ·	lo =00
(-)-Cotinine	100	(-)-Nicotine	2,500
() 0 ::	COTININE		1,0 500
(-)-Cotinine	500	(-)-Nicotine	12,500
() 0 %	COTININE	`, '	1, 050
(-)-Cotinine	50	(-)-Nicotine	1,250
	COTININE	`, '	Ta-a
(-)-Cotinine	10	(-)-Nicotine	250
·	•	DIPHENYLPYRROLIDINE (EDI	
2-Ethylidene-1,5-dimethyl-3,3-			300
		PIPHENYLPYRROLIDINE (EDI	
2-Ethylidene-1,5-dimethyl-3,3-	. , , , ,	,	100
Alfontonid	FENTANYL	` '	00.000
Alfentanyl	>600,000	Buspirone	80,000
Norfentanyl	60	Fentanyl	300
Fenfluramine	150,000	Sufentanyl	150,000
A1641	FENTANYL	` '	ho oos
Alfentanyl	>600,000	Buspirone	30,000
Fenfluramine	100,000	Fentanyl	200
Norfentanyl	40	Sufentanyl	100,000
	FENTANYL	` '	1
Alfentanyl	600,000	Buspirone	15,000
Fenfluramine	50,000	Fentanyl	100
Norfentanyl	20	Sufentanyl	50,000
	FENTANY	1	1
Alfentanyl	600,000	Buspirone	15,000
Fenfluramine	50,000	Fentanyl	100
Norfentanyl	20	Sufentanyl	50,000
paliperidone	1,250	Risperidone	5,000
	FENTANY	L (FYL 10)	
Alfentanyl	300,000	Buspirone	8,000
Fenfluramine	25,000	Fentanyl	50
Norfentanyl	10	Sufentanyl	25,000
paliperidone	500	Risperidone	2,500
Ş	SYNTHETIC MAP	RIJUANA (K2-50)	
JWH-018 5-Pentanoic acid	50	JWH-073 4-butanoic acid	50
JWH-018 4-Hydroxypentyl	400	JWH-018 5-Hydroxypentyl	500
JWH-073 4-Hydroxybuty	500		
	SYNTHETIC MAR	RIJUANA (K2-30)	
JWH-018 5-Pentanoic acid	30	RIJUANA (K2-30) JWH-073 4-butanoic acid	30
		` '	30
JWH-018 5-Pentanoic acid	30	JWH-073 4-butanoic acid	-
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty	30 250 300	JWH-073 4-butanoic acid	-
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty	30 250 300	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl	-
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty	30 250 300 SYNTHETIC MAR	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl	300
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty SJWH-018 5-Pentanoic acid	30 250 300 SYNTHETIC MAR 25	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RIJUANA (K2-25) WH-073 4-butanoic acid	300 25
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty \$\frac{3}{2} JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty	30 250 300 SYNTHETIC MAR 25 200 250	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RIJUANA (K2-25) WH-073 4-butanoic acid	300 25
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty \$\frac{3}{2} JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty	30 250 300 SYNTHETIC MAR 25 200 250	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RIJUANA (K2-25) JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl	300 25
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty \$ JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty 6-M6	30 250 300 SYNTHETIC MAR 25 200 250 ONOACETYLMO	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RIJUANA (K2-25) JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RPHINE (6-MAM 10)	25 250
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty \$ JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty 6-M06-Monoacethylmorphine	30 250 300 SYNTHETIC MAR 25 200 250 ONOACETYLMO 10 THYLENEDIOXY	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RIJUANA (K2-25) JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RPHINE (6-MAM 10) Morphine	25 250
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty S JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty 6-Mc 6-Monoacethylmorphine (±) 3, 4-ME	30 250 300 SYNTHETIC MAR 25 200 250 ONOACETYLMO	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RIJUANA (K2-25) JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RPHINE (6-MAM 10) Morphine MMPHETAMINE (MDA 500)	25 250 100,000
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty S JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty 6-Monoacethylmorphine (±) 3, 4-ME (±) 3,4-ME	30 250 300 SYNTHETIC MAR 25 200 250 ONOACETYLMO 10 THYLENEDIOXY	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RIJUANA (K2-25) JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RPHINE (6-MAM 10) Morphine AMPHETAMINE (MDA 500) Methoxyphenamine	25 250 100,000
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty SJWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty 6-Monoacethylmorphine (±) 3, 4-ME (±) 3,4-Methylenedioxy amphetamine	30 250 300 SYNTHETIC MAR 25 200 250 ONOACETYLMO 10 THYLENEDIOXY	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RIJUANA (K2-25) JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RPHINE (6-MAM 10) Morphine AMPHETAMINE (MDA 500) Methoxyphenamine D-Amphetamine	25 250 100,000 6,000 2,000
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty S JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty 6-Mc 6-Monoacethylmorphine (±) 3, 4-ME (±) 3,4-Methylenedioxy amphetamine D,L-Amphetamine sulfate L-Amphetamine	30 250 300 SYNTHETIC MAR 25 200 250 ONOACETYLMO 10 THYLENEDIOXY 500 300 25,000	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RIJUANA (K2-25) JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RPHINE (6-MAM 10) Morphine AMPHETAMINE (MDA 500) Methoxyphenamine D-Amphetamine Phentermine Maprotiline	25 250 100,000 6,000 2,000 1,000
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty S JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxypentyl JWH-073 4-Hydroxybuty 6-Monoacethylmorphine (±) 3, 4-ME* (±) 3,4-Methylenedioxy amphetamine D,L-Amphetamine sulfate L-Amphetamine	30 250 300 SYNTHETIC MAR 25 200 250 ONOACETYLMO 10 THYLENEDIOXY 500 300 25,000 HYL-β-D-GLUCU	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RIJUANA (K2-25) JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl BRPHINE (6-MAM 10) Morphine AMPHETAMINE (MDA 500) Methoxyphenamine D-Amphetamine Phentermine Maprotiline JRONIDE (ETG 300)	25 250 100,000 6,000 2,000 1,000 50,000
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty S JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxypentyl JWH-073 4-Hydroxybuty 6-Mic 6-Monoacethylmorphine (±) 3, 4-ME* (±) 3,4-Methylenedioxy amphetamine D,L-Amphetamine sulfate L-Amphetamine ETI Ethyl- β-D-Glucuronide	30 250 300 SYNTHETIC MAR 25 200 250 ONOACETYLMO 10 THYLENEDIOXY 500 300 25,000 HYL-β-D-GLUCU	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RIJUANA (K2-25) JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RPHINE (6-MAM 10) Morphine AMPHETAMINE (MDA 500) Methoxyphenamine D-Amphetamine Phentermine Maprotiline RRONIDE (ETG 300) Propyl β-D-glucuronide	25 250 100,000 6,000 2,000 1,000 50,000
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty \$\frac{1}{2}\text{JWH-018 5-Pentanoic acid} JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty 6-Mc 6-Monoacethylmorphine (±) 3, 4-ME* (±) 3,4-ME* (±) 3,4-Methylenedioxy amphetamine D,L-Amphetamine sulfate L-Amphetamine ETI Ethyl- β -D-Glucuronide Morphine 3β-glucuronide	30 250 300 SYNTHETIC MAR 25 200 250 DNOACETYLMO 10 THYLENEDIOXY 500 300 25,000 HYL-β-D-GLUCU 300 60,000	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RIJUANA (K2-25) JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RPHINE (6-MAM 10) Morphine AMPHETAMINE (MDA 500) Methoxyphenamine D-hentermine Maprotiline IRONIDE (ETG 300) Propyl β-D-glucuronide Morphine 6β-glucuronide	25 250 100,000 6,000 2,000 1,000 50,000 30,000 60,000
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty SJWH-018 5-Pentanoic acid JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty 6-Mc 6-Monoacethylmorphine (±) 3, 4-ME (±) 3,4-ME (±) 3,4-Methylenedioxy amphetamine D,L-Amphetamine sulfate L-Amphetamine ETI Ethyl- β -D-Glucuronide Morphine 3β-glucuronide Glucuronic Acid	30 250 300 SYNTHETIC MAP 25 200 250 ONOACETYLMO 10 THYLENEDIOXY 500 300 25,000 HYL-β-D-GLUCU 300 60,000	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RIJUANA (K2-25) JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RPHINE (6-MAM 10) Morphine AMPHETAMINE (MDA 500) Methoxyphenamine D-Amphetamine Phentermine Maprotiline RRONIDE (ETG 300) Propyl β-D-glucuronide	25 250 100,000 6,000 2,000 1,000 50,000
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty SJWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty 6-Mr 6-Monoacethylmorphine (±) 3,4-ME (±) 3,4-ME (±) 3,4-Methylenedioxy amphetamine D,L-Amphetamine sulfate L-Amphetamine ETI Ethyl- β -D-Glucuronide Morphine 3β-glucuronide Glucuronic Acid Methanol	30 250 300 SYNTHETIC MAR 25 200 250 ONOACETYLMO 10 THYLENEDIOXY 500 300 25,000 HYL-β-D-GLUCU 300 60,000 60,000 >100,000	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RIJUANA (K2-25) JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RPHINE (6-MAM 10) Morphine AMPHETAMINE (MDA 500) Methoxyphenamine D-Amphetamine Phentermine Maprotiline IRONIDE (ETG 300) Propyl β-D-glucuronide Morphine 6β-glucuronide Ethanol	25 250 100,000 6,000 2,000 1,000 50,000 30,000 60,000
JWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty SJWH-018 5-Pentanoic acid JWH-018 4-Hydroxypentyl JWH-073 4-Hydroxybuty 6-Mr 6-Monoacethylmorphine (±) 3,4-ME (±) 3,4-ME (±) 3,4-Methylenedioxy amphetamine D,L-Amphetamine sulfate L-Amphetamine ETI Ethyl- β -D-Glucuronide Morphine 3β-glucuronide Glucuronic Acid Methanol	30 250 300 SYNTHETIC MAR 25 200 250 ONOACETYLMO 10 THYLENEDIOXY 500 300 25,000 HYL-β-D-GLUCU 300 60,000 60,000 >100,000	JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RIJUANA (K2-25) JWH-073 4-butanoic acid JWH-018 5-Hydroxypentyl RPHINE (6-MAM 10) Morphine AMPHETAMINE (MDA 500) Methoxyphenamine D-hentermine Maprotiline IRONIDE (ETG 300) Propyl β-D-glucuronide Morphine 6β-glucuronide	25 250 100,000 6,000 2,000 1,000 50,000 30,000 60,000

Glucuronic Acid	100,000	Ethanol	>100,000
Methanol	>100,000	2	- 100,000
		RONIDE (ETG 1,000)	1
Ethyl- β -D-Glucuronide	1,000	Propyl β-D-glucuronide	100,000
Morphine 3β-glucuronide	>100,000	Morphine 6β-glucuronide	>100,000
Glucuronic Acid	>100,000	Ethanol	>100,000
Methanol	>100,000		
ETH		RONIDE (ETG 1,500)	1
Ethyl- β -D-Glucuronide	1,500	Propyl β-D-glucuronide	150,000
Morphine 3β-glucuronide	>100,000	Morphine 6β-glucuronide	>100,000
Glucuronic Acid	>100,000	Ethanol	>100,000
Methanol	>100,000		
		AM (CLO 400)	1
Clonazepam	400	Flunitrazepam	300
Alprazolam	200	(±) Lorazepam	1,250
a-hydroxyalprazolam	2,000	RS-Lorazepamglucuronide	250
Bromazepam	1,000	Midazolam	5,000
Chlordiazepoxide	1,000	Nitrazepam	200
Clobazam	250	Norchlordiazepoxide	200
Clorazepatedipotassium	600	Nordiazepam	1,000
Delorazepam	1,000	Oxazepam	350
Desalkylflurazepam	250	Temazepam	150
Diazepam	300	Triazolam	5,000
Diazeparii Estazolam	1,250	mazuam	5,000
ESIAZOIAIII		AM (CL O 450)	
Olanasanam		AM (CLO 150)	120
Clonazepam	150	Flunitrazepam	_
Alprazolam	75	(±) Lorazepam	500
a-hydroxyalprazolam	750	RS-Lorazepamglucuronide	100
Bromazepam	400	Midazolam	2,000
Chlordiazepoxide	400	Nitrazepam	75
Clobazam	100	Norchlordiazepoxide	75
Clorazepatedipotassium	250	Nordiazepam	400
Delorazepam	400	Oxazepam	130
Desalkylflurazepam	100	Temazepam	60
Diazepam	120	Triazolam	2,000
Estazolam	500		
		THYLAMIDE (LSD 10)	1
Lysergic Acid Diethylamide	10		
		THYLAMIDE (LSD 20)	
Lysergic Acid Diethylamide	20	` '	
, ,	20		
, ,		THYLAMIDE (LSD 50)	
LYSE		THYLAMIDE (LSD 50)	
LYSE Lysergic Acid Diethylamide	FRGIC ACID DIE	THYLAMIDE (LSD 50) DATE (MPD 300)	
LYSE Lysergic Acid Diethylamide	FRGIC ACID DIE		1,000
LYSE Lysergic Acid Diethylamide Methylphenidate (Ritalin)	50 METHYLPHENII	DATE (MPD 300)	1,000
LYSE _ysergic Acid Diethylamide Methylphenidate (Ritalin)	50 METHYLPHENII	DATE (MPD 300) Ritalinic Acid	1,000
LYSE _ysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin)	RGIC ACID DIE 50 METHYLPHENII 300 METHYLPHENII 150	DATE (MPD 300) Ritalinic Acid DATE (MPD 150)	
LYSE _ysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin)	RGIC ACID DIE 50 METHYLPHENII 300 METHYLPHENII 150	DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid	
LYSE _ysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin)	FIGIC ACID DIE 50 METHYLPHENII 300 METHYLPHENII 150 METHYLPHENID 350	DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid DATE (MPD 1,000)	500
LYSE Lysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin)	FIGIC ACID DIE 50 METHYLPHENII 300 METHYLPHENII 150 METHYLPHENID 350	DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid DATE (MPD 1,000) Ritalinic Aicd	500
LYSE Lysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin)	RGIC ACID DIE 50 METHYLPHENII 300 METHYLPHENII 150 METHYLPHENID 350 ZOLPIDEI	DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid DATE (MPD 1,000) Ritalinic Aicd	500
LYSE Lysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin)	RGIC ACID DIE 50 METHYLPHENII 300 METHYLPHENII 150 METHYLPHENID 350 ZOLPIDEI	DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid DATE (MPD 1,000) Ritalinic Aicd M (ZOL 50)	500
LYSE Lysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Zolpidem Mephedrone HCl	RGIC ACID DIE 50 METHYLPHENII 300 METHYLPHENII 150 METHYLPHENID 350 ZOLPIDEI 50 MEPHEDROI	DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid DATE (MPD 1,000) Ritalinic Aicd M (ZOL 50) NE (MEP 500)	500
LYSE _ysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Zolpidem Mephedrone HCl S(-)-Methcathinone HCl	SO	DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid DATE (MPD 1,000) Ritalinic Aicd M (ZOL 50) NE (MEP 500) R(+)-Methcathinone HCl	500 1,000 7,500
LYSE Lysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Zolpidem Mephedrone HCl S(-)-Methcathinone HCl	### REPIECT 1,500	DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid DATE (MPD 1,000) Ritalinic Aid M (ZOL 50) NE (MEP 500) R(+)-Methcathinone HCl 3-Fluoromethcathinone HCl	7,500 7,500
LYSE Lysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Mothylphenidate (Ritalin) Zolpidem Mephedrone HCl S(-)-Methcathinone HCl 4-Fluoromethcathinone HCl	### REPHEDROI ### RE	DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid DATE (MPD 1,000) Ritalinic Aicd M (ZOL 50) NE (MEP 500) R(+)-Methcathinone HCl 3-Fluoromethcathinone HCl Methoxyphenamine NE (MEP 100)	7,500 7,500
LYSE Lysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Zolpidem Mephedrone HCI S(-)-Methcathinone HCI 4-Fluoromethcathinone HCI Mephedrone HCI	### REPIECT	DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid DATE (MPD 1,000) Ritalinic Aicd M (ZOL 50) NE (MEP 500) R(+)-Methcathinone HCl 3-Fluoromethcathinone HCl Methoxyphenamine NE (MEP 100) R(+)-Methcathinone HCl	7,500 7,500 7,500 100,000
LYSE Lysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Zolpidem Mephedrone HCl S(-)-Methcathinone HCl Mephedrone HCl Mephedrone HCl S(-)-Methcathinone HCl	RGIC ACID DIE	DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid DATE (MPD 1,000) Ritalinic Acid DATE (MPD 1,000) Ritalinic Acid M (ZOL 50) NE (MEP 500) R (+)-Methcathinone HCl 3-Fluoromethcathinone HCl Methoxyphenamine NE (MEP 100) R (+)-Methcathinone HCl 3-Fluoromethcathinone HCl	7,500 7,500 100,000 1,500 1,500 1,500
LYSE Lysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Zolpidem Mephedrone HCI S(-)-Methcathinone HCI Mephedrone HCI S(-)-Methcathinone HCI 4-Fluoromethcathinone HCI 4-Fluoromethcathinone HCI	RGIC ACID DIE	DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid DATE (MPD 1,000) Ritalinic Aicd M (ZOL 50) NE (MEP 500) R(+)-Methcathinone HCl 3-Fluoromethcathinone HCl Methoxyphenamine NE (MEP 100) R(+)-Methcathinone HCl 3-Fluoromethcathinone HCl Methoxyphenamine	7,500 7,500 7,500 100,000
LYSE Lysergic Acid Diethylamide Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Methylphenidate (Ritalin) Zolpidem Mephedrone HCI S(-)-Methcathinone HCI Mephedrone HCI S(-)-Methcathinone HCI 4-Fluoromethcathinone HCI 4-Fluoromethcathinone HCI	RGIC ACID DIE	DATE (MPD 300) Ritalinic Acid DATE (MPD 150) Ritalinic Acid DATE (MPD 1,000) Ritalinic Acid DATE (MPD 1,000) Ritalinic Acid M (ZOL 50) NE (MEP 500) R (+)-Methcathinone HCl 3-Fluoromethcathinone HCl Methoxyphenamine NE (MEP 100) R (+)-Methcathinone HCl 3-Fluoromethcathinone HCl	7,500 7,500 100,000 1,500 1,500 1,500

3, 4- methylenedioxy- pyrovalerone	500		
,	IYI ENEDIOYYI	PYROVALERONE (MDPV 300)	1
3, 4- methylenedioxy-	ITELNEDIOXII	FIROVALLINONE (MDF V 300)	
oyrovalerone	300		
-,	DIAZEP	AM (DIA 300)	
Diazepam	300	Midazolam	6.000
Clobazam	200	Nitrazepam	200
Clonazepam	500	Norchlordiazepoxide	100
Clorazepate dipotassium	500	Nordiazepam	900
Alprazolam	100	Flunitrazepam	200
a-hydroxyalprazolam	1.500	(±) Lorazepam	3,000
Bromazepam	900	RS-Lorazepam glucuronide	200
Chlordiazepoxide	900	Triazolam	3,000
Estazolam	6,000	Temazepam	100
Delorazepam	900	Oxazepam	300
Desalkylflurazepam	200	Олагерані	500
Desaikyiiiurazepairi		AM (DIA 200)	1
Diazanam	200	Midazolam	4,000
Diazepam Clobazam	120	Nitrazepam	120
	300	Norchlordiazepoxide	70
Clonazepam		· ·	+
Clorazepate dipotassium	300 70	Nordiazepam Flunitrazepam	600 120
Alprazolam	1,000		1
a-hydroxyalprazolam Bromazonam	600	(±) Lorazepam RS-Lorazepam glucuronide	2,000 120
Bromazepam Chlordiana avida		' '	
Chlordiazepoxide	600	Triazolam	2,000
Estazolam	4,000	Temazepam	70
Delorazepam	600	Oxazepam	200
Desalkylflurazepam	120		
		ONE (ZOP 300)	looo
Zopiclone-x-oxide	300	Zopiclone	300
-		ONE (ZOP 50)	l- o
Zopiclone-x-oxide	50	Zopiclone	50
	1	NONE (MCAT 500)	T
S(-)-Methcathinone HCI	500	R(+)-Methcathinone HCI	1,500
Methoxyphenamine	100,000	3-Fluoromethcathinone HCl	1,500
	1	AZEPAM (7-ACL 300)	L
a-hydroxyalprazolam	6,000	Flunitrazepam	3,000
Bromazepam	6,000	RS-Lorazepam glucuronide	2,700
Chlordiazepoxide	6,000	Norchlordiazepoxide	4,500
Clobazam	9,000	Nordiazepam	15,000
Clonazepam	2,400	Temazepam	9,000
Delorazepam	6,000	7-Aminoclonazepam	300
Desalkylflurazepam	6,000		
	1	AZEPAM (7-ACL 200)	1
a-hydroxyalprazolam	4,000	Flunitrazepam	2,000
Bromazepam	4,000	RS-Lorazepam glucuronide	1,800
Chlordiazepoxide	4,000	Norchlordiazepoxide	3,000
Clobazam	6,000	Nordiazepam	10,000
Clonazepam	1,600	Temazepam	6,000
Delorazepam	4,000	7-Aminoclonazepam	200
Desalkylflurazepam	4,000		
		AZEPAM (7-ACL 100)	
a-hydroxyalprazolam	2,000	Flunitrazepam	1,000
Bromazepam	2,000	RS-Lorazepam glucuronide	900
Chlordiazepoxide	2,000	Norchlordiazepoxide	1,500
Clobazam	3,000	Nordiazepam	5,000
Clonazepam	800	Temazepam	3,000
Delorazepam	2,000	7-Aminoclonazepam	100
	2,000		
Desalkylflurazepam			
Desalkylflurazepam		NYL (CFYL 500)	
Desalkylflurazepam Carfentanyl		NYL (CFYL 500) Fentanyl	100

(±)cis-3-Menthylfentanyl	•		150
	CARFENTANYL	(CFYL 250)	
Carfentanyl	250	Fentanyl	50
Sufentanil	25,000	Ramifentanil	5,000
(±)cis-3-Menthylfentanyl	10,000		75
	CAFFEINE (C	AF 1,000)	
Caffeine	1,000		
	CATHINE (C		
(+)-Norpseudoephedrine HCl (Cathine)	150	(+)3,4-Methylenedioxyamphe tamine (MDA)	100
d/I-Amphetamine	100	p-Hydroxyamphetamine	100
Tryptamine	12,500	Methoxyphenamine	12,500
7.	TROPICAMIDE		
Tropicamide	350		
·	ALPRAZOLAM	(ALP 100)	
Benzodiazepines	300	Flunitrazepam	200
a-hydroxyalprazolam	1,500		3,000
Bromazepam	900	· · ·	200
Chlordiazepoxide	900		6,000
Clobazam	200		200
Clonazepam	500	Norchlordiazepoxide	100
Clorazepatedipotassium	500		900
Delorazepam	900		300
Desalkylflurazepam	200	Temazepam	100
Diazepam	300		3,000
Estazolam	6,000	Alprazolam	100
	PREGABALIN (F		
Pregabalin	50,000		
	PREGABALIN	(PGB 500)	
Pregabalin	500	(. 02 000)	
	ZALEPLON (ZAL 100)	
Zaleplon	100	LAL 100)	
	CANNABINOL	(CNR 500)	
cannabinol	500	Δ ⁹ -THC	10,000
11-nor-Δ ⁹ -THC-9 COOH	300	4 1110	10,000
	GABAPENTIN (GAB 2.000)	
Gabapentin	2,000	1	
- Cabaponan	TRAZODONE	(TZD 200)	
Trazodone	200	(125 200)	
	CARISOPRODOL	(CAR 2 000)	
Carisoprodol	2,000	. (OAR 2,000)	
· · · · · · · · · · · · · · · · · · ·	CARISOPRODOL	(CAR 1 000)	
		. (OAIT 1,000)	
	1 000		
Carisoprodol	1,000	L (CAR 500)	
•	CARISOPRODO	L (CAR 500)	
Carisoprodol	CARISOPRODO 500		
Carisoprodol	CARISOPRODO 500 AB-PINACA	(ABP 10)	10
Carisoprodol AB-PINACA	500 AB-PINACA	(ABP 10) AB-PINACA 5-Pentanoic	10
Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl	CARISOPRODO 500 AB-PINACA 10	(ABP 10) AB-PINACA 5-Pentanoic AB-FUBINACA	10
Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 4-hydroxypentyl	CARISOPRODO 500 AB-PINACA (10) 10 10,000	(ABP 10) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic	10 5,000
Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 4-hydroxypentyl UR-144 5-hydroxypentyl	CARISOPRODO 500 AB-PINACA (10 10 10,000 10,000	(ABP 10) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic UR-144 4-hydroxypentyl	10 5,000 10,000
Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 4-hydroxypentyl UR-144 5-hydroxypentyl APINACA 5-hydroxypentyl	CARISOPRODO 500 AB-PINACA 10 10 10,000 10,000 10,000	(ABP 10) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic UR-144 4-Hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA	10 5,000 10,000 10
Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 4-hydroxypentyl UR-144 5-hydroxypentyl APINACA 5-hydroxypentyl ADB-PINACA	CARISOPRODO 500 AB-PINACA (10 10 10,000 10,000	(ABP 10) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic UR-144 4-hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA	10 5,000 10,000
Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 4-hydroxypentyl UR-144 5-hydroxypentyl APINACA 5-hydroxypentyl ADB-PINACA N-(5-hydroxypentyl)	CARISOPRODO 500 AB-PINACA (10 10,000 10,000 10,000 30	(ABP 10) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic UR-144 4-Hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA	10 5,000 10,000 10
Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 4-hydroxypentyl UR-144 5-hydroxypentyl APINACA 5-hydroxypentyl ADB-PINACA	CARISOPRODO 500 AB-PINACA (10) 10 10,000 10,000 10,000 30 25	(ABP 10) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic UR-144 4-hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA N-(4-hydroxypentyl)	10 5,000 10,000 10
Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 4-hydroxypentyl UR-144 5-hydroxypentyl APINACA 5-hydroxypentyl ADB-PINACA N-(5-hydroxypentyl) 5-fluoro AB-PINACA	CARISOPRODO 500 AB-PINACA (10) 10 10,000 10,000 10,000 30 25 UR-144	(ABP 10) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic UR-144 4-hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA N-(4-hydroxypentyl)	10 5,000 10,000 10 30
Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 4-hydroxypentyl UR-144 5-hydroxypentyl APINACA 5-hydroxypentyl ADB-PINACA N-(5-hydroxypentyl) 5-fluoro AB-PINACA UR-144 5-Pentanoic acid	CARISOPRODO 500 AB-PINACA 10 10 10,000 10,000 10,000 30 25 UR-144 25	(ABP 10) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic UR-144 4-hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA N-(4-hydroxypentyl) (25) UR-144 4-hydroxypentyl	10 5,000 10,000 10 30
Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 4-hydroxypentyl UR-144 5-hydroxypentyl APINACA 5-hydroxypentyl APINACA 5-hydroxypentyl ADB-PINACA N-(5-hydroxypentyl) 5-fluoro AB-PINACA UR-144 5-Pentanoic acid UR-144 5-hydroxypentyl	CARISOPRODO 500 AB-PINACA (10 10,000 10,000 10,000 30 25 UR-144 25 5000	(ABP 10) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic UR-144 4-hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA N-(4-hydroxypentyl) (25) UR-144 4-hydroxypentyl XLR-11 4-hydroxypentyl	10 5,000 10,000 10 30
Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 5-hydroxypentyl UR-144 5-hydroxypentyl APINACA 5-hydroxypentyl ADB-PINACA N-(5-hydroxypentyl) 5-fluoro AB-PINACA UR-144 5-Pentanoic acid UR-144 5-hydroxypentyl 5-fluoro	CARISOPRODO 500 AB-PINACA 10 10 10,000 10,000 10,000 30 25 UR-144 25	(ABP 10) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic UR-144 4-hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA N-(4-hydroxypentyl) (25) UR-144 4-hydroxypentyl XLR-11 4-hydroxypentyl ADB-PINAC	10 5,000 10,000 10 30
Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 4-hydroxypentyl UR-144 5-hydroxypentyl APINACA 5-hydroxypentyl ADB-PINACA N-(5-hydroxypentyl) 5-fluoro AB-PINACA UR-144 5-Pentanoic acid UR-144 5-hydroxypentyl 5-fluoro AB-Pinaca N-(4-hydroxypentyl)	CARISOPRODO 500 AB-PINACA 10 10,000 10,000 10,000 30 25 UR-144 25 5000 10,000	(ABP 10) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic UR-144 4-hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA N-(4-hydroxypentyl) UR-144 4-hydroxypentyl ADB-PINACA UR-144 4-hydroxypentyl ADB-PINAC	10 5,000 10,000 10 30 10,000 2,000
Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 5-hydroxypentyl UR-144 5-hydroxypentyl APINACA 5-hydroxypentyl ADB-PINACA N-(5-hydroxypentyl) 5-fluoro AB-PINACA UR-144 5-Pentanoic acid UR-144 5-hydroxypentyl 5-fluoro	CARISOPRODO 500 AB-PINACA (10 10,000 10,000 10,000 30 25 UR-144 25 5000 10,000 >10,000	(ABP 10) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic UR-144 4-hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA N-(4-hydroxypentyl) UR-144 4-hydroxypentyl ADB-PINAC UR-144 4-hydroxypentyl ADB-PINAC N-(4-hydroxypentyl)	10 5,000 10,000 10 30 10,000 2,000
Carisoprodol AB-PINACA AB-PINACA 5-hydroxypentyl AB-PINACA 4-hydroxypentyl UR-144 5-hydroxypentyl APINACA 5-hydroxypentyl ADB-PINACA N-(5-hydroxypentyl) 5-fluoro AB-PINACA UR-144 5-Pentanoic acid UR-144 5-hydroxypentyl 5-fluoro AB-Pinaca N-(4-hydroxypentyl)	CARISOPRODO 500 AB-PINACA 10 10,000 10,000 10,000 30 25 UR-144 25 5000 10,000	(ABP 10) AB-PINACA 5-Pentanoic AB-FUBINACA UR-144 5-Pentanoic UR-144 4-hydroxypentyl ADB-PINACA Pentanoic Acid 5-fluoro AB-PINACA N-(4-hydroxypentyl) UR-144 4-hydroxypentyl ADB-PINAC UR-144 4-hydroxypentyl ADB-PINAC N-(4-hydroxypentyl)	10 5,000 10,000 10 30 10,000 2,000

Fluoxetine	500		
	KRATOM (F	(RA 300)	
Mitragynine	300	7-hydroxymitragynine	>50,000
	TILIDINE (TLD 50)	
Nortilidine	50	Tilidine	100
ALPHA-PYRROL	IDINOVALEROP	HENONE (α-PVP 2,000)	
Alpha-Pyrrolidinovalerophenone	2,000		
ALPHA-PYRI	ROLIDINOVALER	OPHENONE (α-PVP 1,000)	
Alpha-Pyrrolidinovalerophenone			
		ROPHENONE (α-PVP 500)	
Alpha-Pyrrolidinovalerophenone			
	_	PHENONE (α-PVP 300)	1
Alpha-Pyrrolidinovalerophenone			
	MESCALINE (ME	S 100)	
Mescaline	100		
	MESCALINE (ME	S 300)	ı
Mescaline	300		
	PAPAVERINE (PA		1
Papaverine	500	Diflunisal	1,000,000
Methortrexate	65,000	Methedrone	500,000
Pragablin	500,000	Phenelzine	8,000
Quinine	4,000		
	APENTADOL (TA	IP 1,000)	1
3-((1R,2R)-3-(dimethylamino)-1	1,000		
ethyl-2-methylpropyl)phenol			
	CITALOPRAN	(CIT 500)	1
Desmethylcitalopram	500		
	F-KETAMINE (I	FKET 1,000)	1
-(2-fluorphenyl)-2-methylamino	1,000		
yclohexanone	DIODEDIDONE	(DDD 450)	
None side se	RISPERIDONE	: (KPD 150)	
Risperidone	SCOPOLAMINE	(CCOD 500)	
Conclomino	500	i	3,000
Scopolamine		Atropine AMINE (NND 1,000)	3,000
	1,000	AMINE (NND 1,000)	
N, N-Dimethyltryptamine	/IRTAZAPINE (M	T7 500\	
	500	Mirtazapine	500
N-Desmethylmirtazapine	LANZAPINE (OZ		puu
	1,000	F 1,000)	1
Dlanzapine	ROMORPHONE	(HMO EOO)	
	500	Morphine	200
Hydromorphone Codeine	120	Ethylmorphine	120
JOGGI IG	120	Morphine	120
lydrocodone	500	3-β-D-Glucuronide	250
evorphanol	2,000	Oxycodone	125,000
lormorphine	125,000	Norcodeine	31,200
Oxymorphone	125,000	Nalorphine	50,000
Thebaine	10,000	Diacetylmorphine (Heroin)	250
S-Monoacetylmorphine	120	Piacetyimorphilite (Herolli)	250
	ROMORPHONE	(HMO 300)	1
lydromorphone	300	Morphine	120
Codeine	75	Ethylmorphine	75
		Morphine	
Hydrocodone	300	3-β-D-Glucuronide	150
evorphanol	1,200	Oxycodone	75,000
Vormorphine	75,000	Norcodeine	18,700
Oxymorphone	75,000	Nalorphine	30,000
hebaine	6,000	Diacetylmorphine (Heroin)	150
-Monoacetylmorphine	75		1.55
	ROMORPHONE	(HMO 250)	ı
lydromorphone	250	Morphine	100
Codeine	60	Ethylmorphine	60
-	1	1	1

Hydrocodone	250	Morphine 3-β-D-Glucuronide	125
Levorphanol	1,000	Oxycodone	62,500
Normorphine	62,500	Norcodeine	15,600
Oxymorphone	62,500	Nalorphine	25,000
Thebaine	5,000	Diacetylmorphine (Heroin)	125
6-Monoacetylmorphine	60		

Effect of Urinary Specific Gravity

Fifteen (15) urine samples of normal, high, and low specific gravity ranges (1.005-1.045) were spiked with drugs at 50% below and 50% above cut-off levels respectively. The Multi-Drug Rapid Test was tested in duplicate using fifteen drug-free urine and spiked urine samples. The results demonstrate that varying ranges of urinary specific gravity do not affect the test results.

Effect of Urinary pH

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with drugs at 50% below and 50% above cut-off levels. The spiked, pH-adjusted urine was tested with the Multi-Drug Rapid Test. The results demonstrate that varying ranges of pH do not interfere with the performance of the test.

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free urine or drug positive urine containing above related calibrator substances. The following compounds show no cross-reactivity when tested with the Multi-Drug Rapid Test at a concentration of 100 μ g/mL.

Non Cross-Reacting Compounds

	NOII CIOSS-Read	ting Compounds	
Acetophenetidin	Cortisone	Zomepirac	Quinidine
N-Acetylprocainamide	Creatinine	Ketoprofen	Quinine
Acetylsalicylic acid	Deoxycorticosterone	Labetalol	Salicylic acid
Aminopyrine	Dextromethorphan	Loperamide	Serotonin
Amoxicillin	Diclofenac	Meprobamate	Sulfamethazine
Ampicillin	Diflunisal	Isoxsuprine	Sulindac
I-Ascorbic acid	Digoxin	d,I-Propanolol	Tetracycline
Apomorphine	Diphenhydramine	Nalidixic acid	Tetrahydrocortisone
Aspartame	Ethyl-p-aminobenzoate	Naproxen	3-acetate
Atropine	β-Estradiol	Niacinamide	Tetrahydrocortisone
Benzilic acid	Estrone-3-sulfate	Nifedipine	Tetrahydrozoline
Benzoic acid	Erythromycin	Norethindrone	Thiamine
Bilirubin	Fenoprofen	Noscapine	Thioridazine
d,I-Brompheniramine	Furosemide	d,I-Octopamine	d,I-Tyrosine
Cannabidiol	Gentisic acid	Oxalic acid	Tolbutamide
Chloral hydrate	Hemoglobin	Oxolinic acid	Triamterene
Chloramphenicol	Hydralazine	Oxymetazoline	Trifluoperazine
Chlorothiazide	Hydrochlorothiazide	Papaverine	Trimethoprim
d,I-Chlorpheniramine	Hydrocortisone	Penicillin-G	d,I-Tryptophan
Chlorpromazine	o-Hydroxyhippuric acid	Perphenazine	Uric acid
Cholesterol	3-Hydroxytyramine	Phenelzine	Verapamil
Clonidine	d,l-Isoproterenol	Prednisone	

[ALCOHOL PERFORMANCE CHARACTERISTICS]

The detection limit on the **Urine Alcohol Rapid Test** is from 0.02% to 0.30% for approximate relative blood alcohol level. The cutoff level of the **Urine Alcohol Rapid Test** can vary based on local regulations and laws. Test results can be compared to reference levels with color chart on the foil package.

[ALCOHOL ASSAY SPECIFICITY]

The Urine Alcohol Rapid Test will react with methyl, ethyl and allyl alcohols.

[ALCOHOL INTERFERING SUBSTANCES]

The following substances may interfere with the **Urine Alcohol Rapid Test** when using samples other than urine. The named substances do not normally appear in sufficient quantity in urine to interfere with the test.

- A. Agents which enhance color development
 - Peroxidases

- Strong oxidizers
- B. Agents which inhibit color development
 - Reducing agents: Ascorbic acid, Tannic acid, Pyrogallol, Mercaptans and tosylates, Oxalic acid. Uric Acid
 - Bilirubin

L-dopa

L-methyldopa


Methampyrone

[BIBLIOGRAPHY]

- 1. Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 1986; 1735.
- 2. B. Cody, J.T., "Specimen Adulteration in drug urinalysis. Forensic Sci. Rev., 1990, 2:63.

- 3. C. Tsai, S.C. et.al., J. Anal. Toxicol. 1998; 22 (6): 474
- Hawks RL, CN Chiang. Urine Testing for Drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monograph 73, 1986.
- Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 6th Ed. Biomedical Publ., Foster City,CA 2002.

Index of Symbols





Hangzhou AllTest Biotech Co.,Ltd.

#550, Yinhai Street

Hangzhou Economic & Technological Development Area Hangzhou, 310018 P.R. China

Web: www.alltests.com.cn Email: info@alltests.com.cn





Number: 145038808 Revision date: 2023-03-27